Page last updated: 2024-10-27

gliclazide and Diabetes Mellitus, Adult-Onset

gliclazide has been researched along with Diabetes Mellitus, Adult-Onset in 398 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Research Excerpts

ExcerptRelevanceReference
"To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease."9.30Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. ( Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL, 2019)
"The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)."9.24Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. ( Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D, 2017)
" In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide."9.14Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010)
"Gliclazide has been reported to possess the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels."9.06Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1988)
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia."8.91Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015)
"To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone."7.83Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016)
"To report a case of exposure to gliclazide and ramipril during pregnancy in a patient with diabetes mellitus and hypertension."7.75Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy. ( Akar, M; Kolagasi, O; Sari, F; Sari, R, 2009)
"The effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated."7.66Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment. ( Abe, M; Ikeda, Y; Minami, N, 1983)
"Rosiglitazone plus SU was well tolerated irrespective of hepatitis B and C serological status."6.71Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. ( Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX, 2003)
"Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world."6.67Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991)
"A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high."6.53Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. ( Cao, X; Feng, X; Hu, Y; Jiang, L; Li, Q; Liu, C; Luo, Y; Ma, J; Wang, Y; Yan, R; Yang, F; Yuan, L; Zhao, E; Zhu, Y, 2016)
"Initiation of iGlarLixi resulted in similar TIR, A1C, FPG, weight and hypoglycemia compared with the more affordable option of starting iGlar + gliclazide in adults of South Asian origin with T2D."5.51Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. ( Aronson, R; Bajaj, HS; Bansal, N; Bhela, JS; Brown, RE; Chu, L; Dhillon, G; Gupta, R; Khandwala, H; Padda, JK; Venn, K, 2022)
"Vildagliptin is a new drug used to treat diabetes mellitus (DM)."5.46A case of bullous pemphigoid ınduced by vildagliptin. ( Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G, 2017)
"Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control."5.33Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin. ( Brown, N, 2006)
"To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease."5.30Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. ( Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL, 2019)
"The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)."5.24Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. ( Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D, 2017)
"High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes."5.20Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. ( Abd-Allah, GM; Hassan, MH, 2015)
"Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide."5.19A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. ( Abdallah, K; Hassanein, M; Schweizer, A, 2014)
" In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide."5.14Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010)
"As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk."5.14[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010)
"Over 13 weeks, both repaglinide and gliclazide, when combined with bedtime NPH insulin produce similar significant improvements in glycaemic control (-1%) and similar weight gain."5.10Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. ( Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV, 2003)
"In type 2 diabetic patients, the vasodilating response to forearm ischemia was the same whether patients were treated with diet treatment alone or with glibenclamide or glimepiride at blood glucose-lowering equipotent closes."5.09Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. ( Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P, 2001)
" Plasma glucose and serum insulin, C-peptide, and proinsulin levels were measured before as well as 1 and 2 h after breakfast in 23 patients with non-insulin-dependent diabetes mellitus and 17 patients with impaired glucose tolerance."5.08Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. ( Awata, T; Inoue, I; Katayama, S; Negishi, K; Noji, S; Takahashi, K, 1997)
"Gliclazide has been reported to possess the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels."5.06Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1988)
"Gliclazide has been reported to decrease platelet function and to inhibit the progression of diabetic retinopathy in addition to having a hypoglycemic effect."5.05Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. ( Baba, S; Fukui, I; Goto, Y; Maezawa, H; Nakagawa, S; Sakamoto, N; Takebe, K; Takeda, R, 1983)
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia."4.91Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015)
"Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk."4.91Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. ( Chan, SP; Colagiuri, S, 2015)
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs."4.90Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014)
" The onset of his hypoglycemia occurred within days after starting voriconazole and subsequently fluconazole for a fungal pneumonia."3.88Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report. ( Austin, E; Gunaratne, K; Wu, PE, 2018)
"To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone."3.83Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016)
" Dosage of metformin was maintained throughout the study, and the sulfonylurea was stopped."3.82Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. ( Chang, CC; Chuang, LM; Jiang, YD; Lu, CH; Wang, CY; Wu, HP, 2006)
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009."3.81Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015)
"The risk for hypoglycemia when taking glyburide compared with modified-release gliclazide remains to be established in older adults in routine care."3.81The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. ( Clemens, KK; Dixon, SN; Fleet, JL; Garg, AX; Hramiak, I; McArthur, E, 2015)
"We conducted a population-based cohort study of patients aged 66 years and older who were hospitalized for acute myocardial infarction or who underwent percutaneous coronary intervention between 1 April 2007 and 31 March 2010 while receiving either glyburide or gliclazide."3.78Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. ( Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR, 2012)
"To report a case of exposure to gliclazide and ramipril during pregnancy in a patient with diabetes mellitus and hypertension."3.75Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy. ( Akar, M; Kolagasi, O; Sari, F; Sari, R, 2009)
"Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide."3.74Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007)
"The clinical efficacy of gliclazide and its effect on plasma glucose, body weight and serum lipids was assessed in a 3 months open trial of 30 obese, Non-Insulin Dependent diabetes mellitus (NIDDM) patients who failed to respond to diet therapy alone."3.68Gliclazide in the treatment of obese non-insulin dependent diabetic patients. ( Seshiah, V; Suresh, K; Venkataraman, S, 1993)
"A long-term follow-up study was carried out in 44 Type II diabetic patients to confirm the lack of effect of gliclazide on body weight as well as its hypoglycaemic efficacy and tolerance."3.67Lack of weight gain with gliclazide treatment for 30 months in type II diabetes. ( Lowe, SM; Robb, GH, 1984)
"3% of ideal body weight), with an impaired daily glycaemic profile despite a carbohydrate restrictive diet were treated with gliclazide (40 to 320 mg per day) for 36 months."3.67Is sulphonylurea therapy effective long term? A 3-year study with gliclazide. ( Lavielle, R; Zurro Hernandez, J, 1986)
"The effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated."3.66Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment. ( Abe, M; Ikeda, Y; Minami, N, 1983)
"Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes."2.94The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020)
"Therefore, we compared the renal hemodynamic effects of dapagliflozin with gliclazide in type 2 diabetes."2.94The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. ( Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH, 2020)
"Patients with type 2 diabetes (T2D) are usually treated with (combinations of) glucose-lowering medication."2.94Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. ( Davids, M; Herrema, H; Kramer, MHH; Nieuwdorp, M; van Bommel, EJM; van Raalte, DH, 2020)
"Forty-four people with type 2 diabetes were randomized to 12 weeks of dapagliflozin 10 mg/day or gliclazide 30 mg/day treatment."2.94Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. ( Heerspink, HJL; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Ruiter, D; Smits, MM; Touw, DJ; van Bommel, EJM; van Raalte, DH, 2020)
"Eighty patients with type 2 diabetes and HbA1c between 7."2.90Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients. ( Greco, EL; Greco, G; Negro, R, 2019)
" The incidences of adverse events (AEs) were 29."2.84Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. ( Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D, 2017)
"0%) with a stable dosage of metformin plus gliclazide for more than 3 months were randomized to receive either vildagliptin 50 mg twice daily (BID, n = 37) or saxagliptin 5 mg once daily (QD, n = 36)."2.82Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. ( Jing, W; Shunyou, D; Xiaochun, H; Xiaoyan, C; Yingyu, F; Yuyu, T, 2016)
"We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) clinical trial."2.82Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. ( Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S, 2016)
"Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents attained greater benefit from once-daily insulin glargine plus gliclazide modified release regimen than from a twice-daily premixed insulin regimen."2.80Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. ( Guo, L; Guo, X; Jia, W; Li, Q; Mo, Y; Tian, H; Yang, H; Zhang, M; Zheng, F; Zhou, J, 2015)
"A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1."2.79Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. ( Arima, H; Chalmers, J; Harrap, S; Hirakawa, Y; Mancia, G; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014)
"In patients with type 2 diabetes, moderate alcohol use, particularly wine consumption, is associated with reduced risks of cardiovascular events and all-cause mortality."2.79The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. ( Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014)
"One hundred and one patients with type 2 diabetes who failed to achieve HbA1c<7% on previous metformin monotherapy were included to the study."2.77KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. ( Babjakova, E; Fabianova, M; Javorsky, M; Klimcakova, L; Kozarova, M; Salagovic, J; Schroner, Z; Tkac, I; Tkacova, R; Zidzik, J, 2012)
"A total of 47 newly diagnosed type 2 diabetes patients were randomized 1:1 to receive a 4-week treatment with repaglinide or gliclazide."2.76Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. ( Bu, P; Lei, MX; Liao, EY; Luo, J; Mo, ZH; Xie, YH; Zhang, H, 2011)
"Twenty men with type 2 diabetes (aged 50-70 years) treated with diet, metformin or sulfonylurea alone were recruited from North Glasgow University National Health Service Trusts' diabetes clinics and randomised to either metformin or gliclazide for 10 weeks."2.76AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. ( Boyle, JG; Cleland, SJ; Connell, JM; Jones, GC; Logan, PJ; Salt, IP; Sattar, N; Small, M, 2011)
"Type 2 diabetes has been associated with an increased risk of cancer."2.76Intensive glucose control and risk of cancer in patients with type 2 diabetes. ( Chalmers, J; De Bruin, ML; Grobbee, DE; Kengne, AP; Knol, MJ; Leufkens, HG; Patel, A; Stefansdottir, G; Woodward, M; Zoungas, S, 2011)
" The overall incidence of any adverse events was similar in both groups (approximately 61%), but the number of serious adverse events was higher in the gliclazide group (8."2.75A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. ( Filozof, C; Gautier, JF, 2010)
"Ninety-eight patients with type 2 diabetes and a fasting blood glucose (FBG) levels between 7."2.75Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. ( Chen, Y; Hu, YY; Wu, FZ; Ye, SD; Zhao, LL; Zheng, M, 2010)
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes."2.75Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010)
"In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events."2.75Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010)
"Male and female patients with Type 2 diabetes inadequately managed with metformin or sulfonylurea."2.74Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. ( Brazzale, AR; Mariz, S; Pacini, G; Roden, M, 2009)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."2.73Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
" However, glibenclamide, regardless of the dosage schedule, tends to lower the plasma glucose values between midnight and early morning."2.73Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients. ( Futami-Suda, S; Kigawa, Y; Nakano, H; Norose, J; Oba, K; Ouchi, M; Suzuki, K; Suzuki, T; Watanabe, K; Yasuoka, H, 2008)
"About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks."2.73Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. ( Kuang, H; Liu, X; Xing, H; Yi, R; Zhang, H, 2007)
"Treatment with nateglinide plus metformin for up to 12 months was not associated with weight gain."2.73Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. ( Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P, 2007)
"Gliclazide is an SU agent believed to be more protective."2.73'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas. ( Bilinska, M; Korzeniowska-Kubacka, I; Piotrowicz, R; Potocka, J, 2007)
"In patients with type 2 diabetes, the application of SMBG as an adjunct to oral antidiabetic agent therapy results in further reductions in HbA1c."2.73The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). ( Azizi, F; Barnett, AH; Embong, M; Imamoglu, S; Krentz, AJ; Perusicová, J; Sieradzki, J; Strojek, K; Uliciansky, V; Winkler, G, 2008)
"Gliclazide has been shown to possess free radical scavenging properties."2.72Association of gliclazide and left ventricular mass in type 2 diabetic patients. ( Chang, NC; Huang, CL; Lee, TM; Lin, MS; Pan, NH, 2006)
"Gliclazide MR treatment produced significant reductions in fasting plasma glucose (from 7."2.72Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. ( Drzewoski, J; Zurawska-Klis, M, 2006)
" In responders, the initial dose (30 mg) of the gliclazide MR dosing regimen induced half of the maximum hypoglycaemic effect."2.71Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. ( Francillard, M; Frey, N; Holford, NH; Jochemsen, R; Laveille, C; Paraire, M, 2003)
"Rosiglitazone plus SU was well tolerated irrespective of hepatitis B and C serological status."2.71Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. ( Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX, 2003)
"To compare the metabolic and vascular effects of two sulphonylureas (SU), gliclazide (specific for the pancreatic [SUR1] receptor) and glimepiride (a nonspecific agent that also binds to vascular and cardiac [SUR2] receptors), during chronic administration in metformin-treated patients with Type 2 diabetes (T2DM)."2.71Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study. ( Davis, KR; Dhindsa, P; Donnelly, R, 2003)
"Patients with type 2 diabetes who are inadequately controlled on a half-maximal dose of a sulphonylurea may be managed by either increasing the dose of sulphonylurea or adding another agent."2.71Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. ( Baksi, A; James, RE; Nolan, JJ; Zhou, B, 2004)
"159 patients with type 2 diabetes were parallelly assigned to a slow-released-gliclazide or gliclazide group in a randomized, open, multi-center phase III study to compare the efficacy of slow-released-gliclazide and gliclazide on overall diabetes control through HbA1c and the adverse events including hypoglycemic episodes and change of vital signs, electrocardiogram and clinical laboratory parameters after a 12-week treatment period."2.71[The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus]. ( Gao, Y; Guo, XH; Li, GW; Li, HB; Pan, CY; Tian, H; Xing, XY; Yang, WY; Yuan, SY, 2004)
"An open-label prospective cross-over trial was performed to compare the efficacy and safety of once daily low-dose gliclazide (20 mg/day) with that of nateglinide at the usual dosage (270 mg/day, 90 mg t."2.71Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. ( Kawamori, R; Miwa, S; Ohmura, C; Tanaka, Y; Watada, H, 2004)
"Gliclazide is a sulfonylurea compound oral hypoglycemic drug that has a unique feature of restoring the first-phase insulin secretion, which is lost in T2DM being one of the early features of disease."2.71NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR. ( Brădescu, OM; Gavrilă, L; Guja, C; Ionescu-Tîrgovişte, C, 2004)
"Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities."2.71Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. ( Caumo, A; Cobelli, C; Singhal, P; Taylor, R, 2005)
"Metformin is a well-known oral hypoglycaemic agent and has been commonly used, in combination with sulphonylurea, to treat type 2 diabetes."2.71Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. ( Hayaishi-Okano, R; Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y, 2004)
" After dosing glibenclamide induced a significant (P = 0."2.71Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. ( Boes, U; Wascher, TC, 2005)
"Pioglitazone monotherapy was equivalent to gliclazide in reducing HbA1c, with specific differences between treatments in terms of mechanism of action, plasma lipids and adverse events."2.71A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. ( Brunetti, P; Charbonnel, BH; Hanefeld, M; Matthews, DR; Schernthaner, G, 2005)
"Metformin treatment showed either small mean increases or decreases."2.71Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. ( Belcher, G; Schernthaner, G, 2005)
" The objective of the DIACOM (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes) study was to compare the compliance of patients treated with once-daily (od) or twice-daily (bid) sulphonylureas."2.71The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). ( Kardas, P, 2005)
"In conclusion, in long-standing type 2 diabetes the acute administration of gliclazide significantly enhances second phase insulin release at a moderately elevated blood glucose level."2.70Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus. ( Ligtenberg, JJ; Reitsma, WD; van Haeften, TW, 2001)
"To this end, 10 patients with type 2 diabetes (age 53 +/- 2 years, BMI 27."2.70Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. ( Hansen , AP; Juhl, CB; Pincus, SM; Pørksen, N; Schmitz, O; Veldhuis, JD, 2001)
"Fifty patients of uncontrolled type 2 diabetes were divided in to two groups."2.70Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study. ( Chugh, K; Chugh, SN; Dhawan, R; Kishore, K; Sharma, A, 2001)
"Fifty-seven patients affected by type 2 diabetes for at least 5 years, aged 61."2.69[Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data]. ( Arcangeli, A; Fiore, G; Galeone, F; Mannucci, E, 1998)
"Forty patients with type 2 diabetes mellitus who were on conventional insulin therapy (subcutaneous insulin therapy consisting of regular and NPH insulin, two times a day) were included in the study."2.69Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. ( Gedik, O; Güvener, N, 1999)
" Patients were randomly assigned to sulphonylurea increased up to its maximum dosage (1st group) or to addition of metformin (2nd group)."2.69Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. ( Ambrosi, F; Carle, F; Filipponi, P; Gregorio, F; Manfrini, S; Merante, D; Testa, R; Velussi, M, 1999)
"Gliclazide was measured using h."2.69Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. ( Barrett, PH; Beilby, JP; Daly, F; Davis, TM; Dusci, LJ; Ilett, KF; Walsh, JP, 2000)
"Fifty-three Chinese patients with NIDDM (mean age 53."2.68Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. ( Chow, CC; Cockram, CS; Sorensen, JP; Tsang, LW, 1995)
" Moreover adding a bed-time dosage to the standard administration at meal times seems to be an effective therapeutical strategy."2.68Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study. ( Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Santucci, A, 1997)
"Subjects with NIDDM have increased plasma proinsulin concentrations, compared with nondiabetic subjects, both in absolute terms and as a proportion of circulating insulin-like molecules."2.68Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. ( Barrow, BA; Levy, JC; Manley, SE; Rachman, J; Turner, RC, 1997)
"Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily."2.67Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. ( Kruseman, AC; Menheere, PP; Müller, PG; Nijst, L; Sels, JP; Wolffenbuttel, BH, 1993)
" The dosage was adjusted to obtain adequate control or up to the maximum recommended dosage."2.67Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. ( Harrower, AD, 1991)
"Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world."2.67Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991)
"Gliclazide was significantly better than glipizide (p less than 0."2.67Comparison of secondary failure rate between three second generation sulphonylureas. ( Harrower, AD; Wong, C, 1990)
"A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high."2.53Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. ( Cao, X; Feng, X; Hu, Y; Jiang, L; Li, Q; Liu, C; Luo, Y; Ma, J; Wang, Y; Yan, R; Yang, F; Yuan, L; Zhao, E; Zhu, Y, 2016)
"The primary aim must be the treatment of the insulin resistance."2.43[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005)
"Pioglitazone is a TZD that provides appropriate monotherapy or combination treatment for patients with type 2 diabetes."2.42Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. ( Campbell, IW, 2004)
"The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments."2.42Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004)
" The absorption rate of glibenclamide and tolbutamide was not affected by food."2.41[Timing of administration of sulfonyl urea derivatives]. ( de Smet, PA; Fischer, HR, 2000)
" Employing an innovative pharmaceutical form based on a hydrophilic matrix to deliver this short-acting sulfonylurea, gliclazide modified release is associated with an unsurpassed efficacy:acceptability ratio, with the potential additional advantages inherent in reduced dosage and once-daily administration."2.41Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. ( Harrower, A, 2000)
"Gliclazide MR has also demonstrated antioxidant properties that are independent of glycaemic control."2.41Gliclazide modified release. ( Goa, KL; McGavin, JK; Perry, CM, 2002)
"Gliclazide is a second-generation sulfonylures that is widely used in the treatment of non-insulin-dependent diabetes mellitus (Type 2 diabetes)."2.39[Gliclazide: review of metabolic and vascular action]. ( Alberti, KG, 1994)
"Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)."2.38Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. ( Brogden, RN; Palmer, KJ, 1993)
"Gliclazide is a second-generation sulfonylurea that is widely used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)."2.38Gliclazide: metabolic and vascular effects--a perspective. ( Alberti, KG; Johnson, AB; Taylor, R, 1992)
"Many NIDDM patients exhibit poor compliance with regard to exercise and diet, and require oral hypoglycemics."2.38The treatment of NIDDM in the decade of the 90s. ( Krall, LP, 1991)
"Gliclazide is a sulphonylurea drug with an intermediate half-life of around 11 hours."2.38The mode of action and clinical pharmacology of gliclazide: a review. ( Campbell, DB; Lavielle, R; Nathan, C, 1991)
"Treatment with gliclazide of patients with NIDDM has been shown to be associated with a potentiation of both insulin-mediated glucose disposal and insulin-stimulated glycogen synthase activity in skeletal muscle."2.38Gliclazide and insulin action in human muscle. ( Bak, JF; Pedersen, O, 1991)
"Gliclazide is a second-generation sulfonylurea drug whose efficacy in the treatment of NIDDM, alone or in combination with insulin, has been widely demonstrated."2.38Current status of non-insulin-dependent diabetes mellitus (type II): management with gliclazide. ( Rifkin, H, 1991)
"Gliclazide was approved as a treatment for type 2 diabetes in an era before model-based drug development, and consequently, the recommended doses were not optimised with modern methods."1.91Optimal dosing of gliclazide-A model-based approach. ( Cotton, MF; Hussein, H; Karamchand, S; Kjellsson, MC; Leisegang, R; Mim, SR; Naidoo, P; Rambiritch, V; Vidadi, S, 2023)
"A post hoc analysis of patients with type 2 diabetes followed by the ADVANCE-ON (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - Observational Study)."1.72Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. ( Chalmers, J; Hamet, P; Harrap, S; Harris, K; Mancia, G; Poulter, N; Rodgers, A; Wang, N; Williams, B; Woodward, M; Zoungas, S, 2022)
"Non-alcoholic fatty liver disease (NAFLD) was evaluated by abdominal ultrasound, and fibrosis stages were evaluated at baseline and 8 months."1.72The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. ( Fu, BY; Wang, XJ, 2022)
" The solubility, dissolution rate and bioavailability of gliclazide SGNCs were significantly improved compared to pure gliclazide."1.51Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ( Bhattamisra, SK; Krishnamoorthy, R; Panda, BP; Patnaik, S; Seng, LB; Shivashekaregowda, NKH, 2019)
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues."1.51Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019)
"To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with metformin and/or gliclazide."1.48Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. ( Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M, 2018)
" It is dosed in modified release tablets."1.48Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients. ( Czyrski, A; Hermann, T; Resztak, M, 2018)
"Diabetic ketoacidosis has been described as a rare complication of acromegaly and may be observed in 1% of affected patients."1.46Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. ( Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D, 2017)
"Vildagliptin is a new drug used to treat diabetes mellitus (DM)."1.46A case of bullous pemphigoid ınduced by vildagliptin. ( Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G, 2017)
"The objective of this study was to determine if there is a dose-response relationship between sulfonylureas and major adverse cardiovascular events (MACE)."1.43Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. ( Abdelmoneim, AS; Eurich, DT; Qiu, W; Senthilselvan, A; Simpson, SH, 2016)
"A total of 746 incident type 2 diabetes patients were included in this study."1.43CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. ( Chen, D; Chen, P; Guo, Y; Han, C; Liu, Z; Zeng, W, 2016)
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."1.43Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016)
"In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae."1.42Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015)
"In primary care, once daily, breakable extended release gliclazide XR 60 mg, with a simple two step titration to administer maximum recommended dosage is effective in achieving short term glycemic control with a low frequency of hypoglycaemia, in monotherapy or in combination with metformin."1.42Treatment of Type 2 Diabetes with a Breakable Extended Release Gliclazide Formulation in Primary Care: The Xrise Study. ( Chopra, V; Jain, S; Jayaprakashsai, J; Mohan, V; Sanyal, D, 2015)
"Gliclazide or metformin-treated patients demonstrated lesser mortality risk than glibenclamide-treated ones in all four evaluation models, but age and duration stratification can influence this phenomenon in case of "first prescription model"."1.40Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients. ( Khalangot, M; Kovtun, V, 2014)
"Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury."1.37Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011)
"Often misdiagnosed as type 1 or type 2 diabetes, maturity-onset diabetes of the young (MODY) is the most common form of monogenic diabetes, accounting for 1-2% of all diabetes cases."1.37Diagnosis in diabetes: does it matter? ( Robertson, L; Swaminathan, K; Thethy, I, 2011)
" Long-term use of metformin in complex multifactorial therapy of women with decompensated type 2 diabetes DM, AH and abdominal obesity provides improvement of carbohydrate and lipid metabolism, lowering of arterial pressure, diminishment of albuminuria, diastolic dysfunction, and stiffness of left ventricular myocardium."1.36[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010)
"Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties."1.36Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. ( Chan, JC; Chow, CC; Ko, GT; Kong, AP; Luk, AO; Ma, RC; Ng, VW; Ozaki, R; So, WY; Tong, PC; Yang, X; Yu, LW, 2010)
"The study objective was to determine if Ramadan fasting was safe in patients with type 2 diabetes mellitus (T2D), based upon a determination of the effect of fasting on a broad range of physiological and clinical parameters, including markers of glycemic control and blood pressure."1.35Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control? ( Chabraoui, L; Chebraoui, L; Chraibi, A; El Guessabi, L; Fellat, S; Israili, ZH; Lyoussi, B; M'guil, M; Ragala, MA, 2008)
" Subsequently, the effects of a 1-week chronic daily dosing of DPP-IV inhibitors and sulfonylureas were investigated."1.35Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. ( Hayakawa, M; Matsuyama-Yokono, A; Nakano, R; Shibasaki, M; Shiraki, K; Someya, Y; Tahara, A, 2009)
"gliclazide treatment."1.35Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009)
"Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring."1.35Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009)
"Type 2 diabetes mellitus is associated with elevated level of oxidative stress, which is one of the most important factors responsible for the development of chronic complications of this disease."1.35In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). ( Blasiak, J; Drzewoski, J; Kasznicki, J; Sliwinska, A, 2008)
"A 74-year-old woman with type 2 diabetes mellitus who had been treated with a sulfonylurea for 6 years began experiencing frequent episodes of hypoglycemia."1.34Insulinoma causing hypoglycemia in a patient with type 2 diabetes. ( Chang, WH; Chen, TL; Lei, WY; Wang, CY; Wang, TE; Yang, TL, 2007)
"Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder."1.33A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006)
"Gliclazide is an oral hypoglycemic agent that belongs to the class of sulfonylureas: basic and clinical evidences suggest that gliclazide works as an antioxidative drug, independently from its ability to reduce hyperglycemia."1.33Effects of gliclazide beyond metabolic control. ( Ceriello, A, 2006)
"Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control."1.33Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin. ( Brown, N, 2006)
"Insulin resistance is a key feature of type 2 diabetes mellitus."1.32Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide. ( Antić, S; Bogicević, M; Milojković, M; Mitić-Zlatković, M; Stefanović, V; Stojiljković, S; Vlahović, P, 2003)
"8%, and increase in percentage of once-daily dosing regimen from 12 to 58."1.32[Compliance and optimisation of oral antidiabetic therapy. A longitudinal study]. ( Guillausseau, PJ, 2004)
"Weight reduction was observed in all the treatment groups."1.32[Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?]. ( Stalder, Dde M, 2004)
"The subjects were 55 patients with type 2 diabetes."1.31Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. ( Kubo, K, 2002)
" All patients were stable, with no change in dosage for at least 3 months."1.30Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination. ( Guillausseau, PJ, 1997)
"In gliclazide-treated NIDDM patients, PDH activity in circulating lymphocytes recovered."1.30Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus. ( Bruno, R; Curto, M; Gamba, S; Mioletti, S; Mostert, M; Piccinini, M; Rabbone, I; Rinaudo, MT, 1998)
"Gliclazide treatment lowered LPS-stimulated TNF-alpha production by diabetic monocytes to levels similar to those observed in control subjects."1.30Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. ( Desfaits, AC; Renier, G; Serri, O, 1998)
"Gliclazide-treated Goto-Kakisaki rats were evaluated against Wistar and untreated Goto-Kakisaki rats."1.30Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats. ( Bailbé, D; Dachicourt, N; Gangnerau, MN; Portha, B; Ravel, D; Serradas, P, 1998)
"The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops."1.30Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. ( Muggeo, M, 1998)
"Gliclazide treatment results in increased serum C-peptide, decreased hemoglobin-A1c, decreased glucose excursion on glucose tolerance test, and 35% increased insulin-stimulated glucose disposal."1.29Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study. ( Bjørbaek, C; Hansen, L; Kahn, BB; Pedersen, O; Rosen, AS; Vestergaard, H; Weinreb, JE, 1995)
"Gliclazide was applied in the group I (11 patients, mean age 63."1.29[Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?]. ( Bresler, M; Grzeszczak, W; Gumprecht, J; Strojek, K; Trautsolt, W, 1993)
"Five male non-obese newly diagnosed NIDDM and 5 age-, sex- and body mass index (BMI) matched healthy controls without a family history of diabetes were submitted to a frequently sampled intravenous (i."1.29Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM). ( Porrelli, RN; Santomauro, AT; Wajchenberg, BL, 1993)
"Gliclazide treatment was associated with significant reductions in HbA1C (p=0."1.29Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control. ( Bjørbaek, C; Lund, S; Pedersen, O; Vestergaard, H, 1995)
" Thus the insulinogenic effect of gliclazide could be masked during long-term administration by a concomitant effect of gliclazide which increases hepatic extraction of insulin."1.28Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus. ( Borghi, VC; Giannella-Neto, D; Porrelli, RN; Santomauro, AT; Wajchenberg, BL, 1992)
"Gliclazide was given to group A following CSII and to 5 obese NIDDM patients (group B) in their habitual hyperglycemic state."1.28Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991)
" Adverse effects were reported by 22 patients, including dizziness and light-headedness, diarrhea, nausea, palpitations and pruritus, but none required modification of Diamicron therapy."1.28Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. ( Dudley, J; Kalb, B; Kilo, C, 1991)
"Gliclazide was given to group A following CSII, and to five obese NIDDM patients (group B) in their habitual hyperglycemic state."1.28Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991)
"Gliclazide was given 30 min before, at the start of and 30 min after breakfast or omitted altogether."1.28The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels. ( Batch, J; Bird, D; Cameron, D; Charles, B; Ma, A; Noble, R; Ravenscroft, P, 1990)
" Gliclazide taken 30 minutes before breakfast increased in serum concentration before the meal-induced hyperglycemia, but that taken just before or just after breakfast was poorly absorbed and showed smaller and greatly delayed peaks."1.28The effect of timing on gliclazide absorption and action. ( Ishibashi, F; Takashina, S, 1990)
"Gliclazide treatment was associated with improved glycemic control and enhanced pancreatic beta-cell responses to meal stimulation."1.28Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. ( Bak, JF; Pedersen, O; Schmitz, O; Sørensen, NS, 1989)
"Gliclazide (80 mg bd) was administered to nine subjects with type 2 (non insulin dependent) diabetes inadequately controlled on diet only."1.28The effects of long term gliclazide administration on insulin secretion and insulin sensitivity. ( Bird, D; Cameron, DP; Howlett, V; Kamp, M; Ma, A, 1989)
"Mean body weight was reduced, particularly in obese and elderly subjects and those treated previously with sulphonylurea drugs."1.27Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. ( Campbell, DB; Shaw, KM; Ward, JD; Wheeley, MS, 1985)
"Gliclazide is a suitable oral hypoglycaemic agent for use in the obese diabetic who cannot be controlled by diet alone."1.27A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. ( Frier, BM; Kay, JW; McAlpine, CH; McAlpine, LG; Storer, AM; Waclawski, ER, 1988)
"Gliclazide was proven to be a reliable blood-sugar lowering agent with a generally good subjective tolerance."1.27[Gliclazide in the non-insulin-dependent diabetic patient in geriatrics]. ( Böhmer, F; Frühwald, T, 1988)

Research

Studies (398)

TimeframeStudies, this research(%)All Research%
pre-199042 (10.55)18.7374
1990's90 (22.61)18.2507
2000's125 (31.41)29.6817
2010's111 (27.89)24.3611
2020's30 (7.54)2.80

Authors

AuthorsStudies
Kumar, A1
Maurya, RA1
Sharma, S2
Ahmad, P1
Singh, AB1
Tamrakar, AK1
Srivastava, AK1
Raza, SA1
Akram, J1
Aamir, AH1
Ahmedani, Y1
Hassan, MI1
Soelistijo, SA1
Aman, AM1
Zufry, H1
Pranoto, A1
Rudijanto, A1
Hassanien, M1
Bajaj, HS1
Chu, L1
Bansal, N1
Brown, RE1
Dhillon, G1
Gupta, R1
Bhela, JS1
Padda, JK1
Khandwala, H1
Venn, K1
Aronson, R1
Ohkuma, T3
Harris, K2
Cooper, M7
Grobbee, DE7
Hamet, P14
Harrap, S17
Mancia, G15
Marre, M15
Patel, A16
Rodgers, A6
Williams, B12
Woodward, M25
Chalmers, J28
Wang, N1
Poulter, N17
Zoungas, S21
Tomlinson, B1
Li, YH1
Chan, P1
Solanki, R1
Wadhwana, P1
Patel, R1
Gayakvad, B1
Kothari, C1
Patel, C1
Mim, SR1
Hussein, H1
Vidadi, S1
Leisegang, R1
Karamchand, S1
Rambiritch, V2
Cotton, MF1
Naidoo, P2
Kjellsson, MC1
Paz-Pacheco, E1
Nevado, J1
Paz, EMC1
Jasul, G1
Aman, AYC1
Alejandro-Ribaya, EL1
Francisco, MD1
Guanzon, MLV1
Uyking-Naranjo, M1
Añonuevo-Cruz, C1
Maningat, MPD1
Jaring, C1
Nacpil-Dominguez, P1
Pala-Mohamad, A1
Uy-Canto, A1
Quisumbing, JP1
Lat, AM1
Bernardo, DC1
Mansibang, NM1
Ribaya, VS1
Calpito, KJA1
Ferrer, JP1
Biwang, J1
Melegrito, J1
Deguit, CD1
Panerio, CE1
Lim, LL1
S H Lau, E1
Pheng Chan, S1
Ji, L2
Lim, S1
Sirinvaravong, S1
Unnikrishnan, AG1
O Y Luk, A1
Cortese, V2
Durocher, A1
C N Chan, J1
Kalra, S2
Lee, AK1
Wang, D2
Warren, B1
Sharrett, AR1
Mcevoy, JW2
Selvin, E2
Ungurianu, A1
Şeremet, O1
Gagniuc, E1
Olaru, OT1
Guţu, C1
Grǎdinaru, D1
Ionescu-Tȋrgovişte, C2
Marginǎ, D1
Dǎnciulescu-Miulescu, R1
Vianna, AGD2
Lacerda, CS2
Pechmann, LM2
Polesel, MG2
Marino, EC2
Scharf, M1
Detsch, JM1
Marques, K1
Sanches, CP1
Panda, BP1
Krishnamoorthy, R1
Bhattamisra, SK1
Shivashekaregowda, NKH1
Seng, LB1
Patnaik, S1
van Bommel, EJM4
Muskiet, MHA3
van Baar, MJB1
Tonneijck, L1
Smits, MM2
Emanuel, AL1
Bozovic, A1
Danser, AHJ2
Geurts, F2
Hoorn, EJ2
Touw, DJ3
Larsen, EL1
Poulsen, HE1
Kramer, MHH4
Nieuwdorp, M4
Joles, JA3
van Raalte, DH4
Mifsud, S1
Schembri, EL1
Fava, S1
Herrema, H1
Davids, M1
Mathavan, S1
Ionescu, CM1
Kovacevic, B1
Mikov, M1
Golocorbin-Kon, S1
Mooranian, A1
Dass, CR1
Al-Salami, H1
Tian, J1
Wang, JG1
Ruiter, D1
Heerspink, HJL1
Saberi, M1
Ramazani, Z1
Rashidi, H1
Saberi, A1
Cho, EH1
Han, K1
Kim, B1
Lee, DH1
Zaccardi, F1
Jacquot, E1
Tyrer, F1
Seidu, S1
Davies, MJ2
Khunti, K1
Gao, S1
Chen, Y2
Hu, R1
Lu, W1
Yu, L1
Chen, J1
Liu, S1
Guo, Y2
Shen, Q1
Wang, B1
Fang, W1
Lee, KF1
Mak, MWH1
Lao, VWN1
Yip, HLK1
Lau, WY1
Wong, VTL1
Post, A1
Bakker, SJL1
van Berkel, M1
Ferrannini, E1
Morieri, ML1
Vitturi, N1
Avogaro, A3
Targher, G1
Fadini, GP2
Cordiner, RLM2
Mari, A1
Tura, A1
Pearson, ER3
Fu, BY1
Wang, XJ1
Huang, X1
Zhou, Y2
Tang, H1
Liu, B1
Su, B1
Wang, Q1
Quarella, M1
Walser, D1
Brändle, M1
Fournier, JY1
Bilz, S1
Feng, W1
Gao, C1
Bi, Y3
Wu, M1
Li, P2
Shen, S1
Chen, W1
Yin, T1
Zhu, D2
Mohammedi, K3
Colagiuri, S5
Das, AK1
Douros, A1
Yin, H1
Yu, OHY1
Filion, KB1
Azoulay, L1
Suissa, S1
van Steen, SC1
Li, Q13
Cooper, ME4
DeVries, JH1
Hu, C2
Zhao, X1
Luo, P1
Lu, J2
Chen, M2
Yan, D1
Lu, X1
Kong, H1
Jia, W3
Xu, G1
Zatti, G1
Baldi, I1
Bottigliengo, D1
Consoli, A1
Giaccari, A1
Sesti, G2
Heald, AH1
Livingston, M1
Bien, Z1
Moreno, GYC1
Laing, I1
Stedman, M1
Cozzani, E1
Di Zenzo, G1
Cioni, M1
Javor, S1
Altieri, M1
Anselmi, L1
Parodi, A1
Negro, R1
Greco, EL1
Greco, G1
Faria-Neto, JR1
Gunaratne, K1
Austin, E1
Wu, PE1
Matthews, D2
Leiter, LA2
Chan, SP2
Garcia de Lucas, MD1
Pérez Belmonte, LM1
Suárez Tembra, M1
Olalla Sierra, J1
Gómez Huelgas, R1
Feng, WH1
Yin, TT1
Gao, CX1
Shen, SM1
Gao, LJ1
Yang, DH2
Zhu, DL1
Challier, C1
Laurella, S1
Allegretti, P1
Sabini, C1
Sabini, L1
García, NA1
Biasutti, A1
Criado, S1
Czyrski, A1
Resztak, M1
Hermann, T1
Juraschek, SP1
Lazo, M1
Huang, HK1
Yeh, JI1
Lee, JY1
Jang, SY1
Nam, CM1
Kang, ES2
Sekeroglu, MA1
Taylan Sekeroglu, H1
Bo, S1
Castiglione, A1
Ghigo, E1
Gentile, L1
Durazzo, M1
Cavallo-Perin, P1
Ciccone, G1
Abdelmoneim, AS4
Eurich, DT2
Gamble, JM1
Johnson, JA1
Seubert, JM2
Qiu, W3
Simpson, SH4
Konig, M1
Lamos, EM1
Stein, SA1
Davis, SN1
Pu, R1
Geng, XN1
Yu, F3
Liang, HG1
Shi, LW1
Contreras-Steyls, M1
Vílchez-Márquez, F1
Mota, A1
Moyano, B1
Herrera-Ceballos, E1
Arima, H3
Hirakawa, Y5
Yamout, H1
Bakris, GL1
Landman, GW2
de Bock, GH1
van Hateren, KJ2
van Dijk, PR1
Groenier, KH2
Gans, RO1
Houweling, ST1
Bilo, HJ1
Kleefstra, N2
Blomster, JI1
Chow, CK1
Neal, B11
Hillis, GS1
Pareek, A1
Chandurkar, N1
Thomas, N1
Viswanathan, V1
Deshpande, A1
Gupta, OP1
Shah, A1
Kakrani, A1
Bhandari, S1
Thulasidharan, NK1
Saboo, B1
Devaramani, S1
Vijaykumar, NB1
Agrawal, N1
Mahesh, M1
Kothari, K1
Erem, C1
Ozbas, HM1
Nuhoglu, I1
Deger, O1
Civan, N1
Ersoz, HO1
Ninomiya, T3
Hassanein, M3
Abdallah, K1
Schweizer, A1
Zhao, F1
Ma, YF1
Wen, JX1
DU, YF1
Li, CL1
Li, GW3
Billot, L4
Monaghan, H1
Joshi, R4
Glasziou, P4
Grobbee, D3
Heller, S7
Lisheng, L4
Matthews, DR8
Mogensen, CE2
Perkovic, V5
MacMahon, S7
van der Leeuw, J2
Visseren, FL2
Kengne, AP6
van der Graaf, Y2
Khalangot, M2
Kovtun, V2
Mogensen, UM1
Andersson, C1
Fosbøl, EL1
Schramm, TK1
Vaag, A1
Scheller, NM1
Torp-Pedersen, C1
Gislason, G1
Køber, L1
Huang, Y1
Light, P1
Lee, YH1
Lee, CJ1
Lee, HS1
Choe, EY1
Lee, BW1
Ahn, CW1
Cha, BS1
Lee, HC1
Balkau, B1
Winkler, G2
Clemens, KK1
McArthur, E1
Dixon, SN1
Fleet, JL1
Hramiak, I1
Garg, AX1
Zhou, J1
Zheng, F1
Guo, X1
Yang, H1
Zhang, M1
Tian, H3
Guo, L1
Mo, Y1
Mbanya, JC1
Al-Sifri, S1
Abdel-Rahim, A1
Satman, I3
Hassan, MH1
Abd-Allah, GM1
Oei, E1
Samad, N1
Visser, A1
Chowdhury, TA2
Fan, SL1
Shestakova, MV1
Trubitsyna, NP1
Piletič, M1
Grobbee, R1
Jardine, M1
Singh, AK2
Singh, R1
Xiaoyan, C1
Jing, W1
Xiaochun, H1
Yuyu, T1
Shunyou, D1
Yingyu, F1
García Díaz, E1
Guagnozzi, D1
Gutiérrez, V1
Mendoza, C1
Maza, C1
Larrañaga, Y1
Perdomo, D1
Godoy, T1
Taleb, G1
Wong, MG1
Senthilselvan, A1
Zeng, W1
Chen, P1
Liu, Z1
Chen, D1
Han, C1
Juszczak, A1
Pryse, R1
Schuman, A1
Owen, KR1
Anderson, AJ1
Andrew, R1
Homer, NZ1
Jones, GC2
Smith, K1
Livingstone, DE1
Walker, BR1
Stimson, RH1
Keseroglu, HO1
Taş-Aygar, G1
Gönül, M1
Gököz, O1
Ersoy-Evans, S1
Alam, F1
Islam, MA1
Kamal, MA1
Gan, SH1
van Dijk, P1
Bouma, A1
Bilo, H1
Mohan, V1
Chopra, V1
Sanyal, D1
Jain, S1
Jayaprakashsai, J1
Tang, TT1
Jiang, F1
Zhang, R1
Yin, J1
Bao, YQ1
Cheng, X1
Jia, WP2
Feng, X1
Yuan, L1
Hu, Y1
Zhu, Y1
Yang, F1
Jiang, L1
Yan, R1
Luo, Y1
Zhao, E1
Liu, C1
Wang, Y1
Cao, X1
Ma, J1
Xu, W1
Mu, Y1
Zhao, J1
Ji, Q1
Zhou, Z1
Yao, B1
Mao, A1
Engel, SS1
Zhao, B1
Zeng, L1
Ran, X1
Yang, W1
Weng, J1
Liu, L2
Pan, C2
Bompoint, S1
de Galan, BE5
Travert, F3
Feng, Y2
Mao, G1
Ren, X1
Xing, H2
Tang, G1
Li, X1
Sun, L1
Yang, J1
Ma, W1
Wang, X1
Xu, X1
M'guil, M1
Ragala, MA1
El Guessabi, L1
Fellat, S1
Chraibi, A1
Chabraoui, L1
Chebraoui, L1
Israili, ZH1
Lyoussi, B1
Chandra, ST1
Priya, G1
Khurana, ML1
Jyotsna, VP1
Sreenivas, V1
Dwivedi, S1
Ammini, AC1
Kigawa, Y1
Oba, K1
Futami-Suda, S1
Norose, J1
Yasuoka, H1
Suzuki, K1
Ouchi, M1
Watanabe, K1
Suzuki, T1
Nakano, H1
Monami, M2
Lamanna, C2
Balzi, D2
Marchionni, N2
Mannucci, E5
Kolagasi, O1
Sari, F1
Akar, M1
Sari, R1
Matsuyama-Yokono, A1
Tahara, A1
Nakano, R1
Someya, Y1
Shiraki, K1
Hayakawa, M1
Shibasaki, M1
Walker, J1
White, R1
Vale, A1
Elliott, S1
Wass, J1
Reynolds, J1
Lumb, AN1
Gallen, IW1
Roden, M2
Mariz, S4
Brazzale, AR1
Pacini, G1
Poulter, NR1
Slim, R1
Ben Salem, C1
Zamy, M1
Zami, M1
Biour, M1
Cass, A1
Pillai, A3
Devendra, D1
Gohel, B1
Bravis, V1
Hui, E1
Salih, S1
Mehar, S1
Anderson, C1
Dufouil, C1
Hackett, M1
Heller, SR1
Pan, CY4
Foley, JE1
Sreenan, S1
Tronko, M1
Kravchenko, V1
Li, Y1
Xu, L1
Shen, J1
Ran, J1
Zhang, Y1
Wang, M1
Yan, L2
Cheng, H2
Fu, Z1
Konya, H1
Hasegawa, Y1
Hamaguchi, T1
Satani, K1
Umehara, A1
Katsuno, T1
Ishikawa, T1
Miuchi, M1
Kohri, K1
Suehiro, A1
Kakishita, E1
Miyagawa, J1
Namba, M1
Arai, K1
Matoba, K1
Hirao, K1
Matsuba, I1
Takai, M1
Takeda, H1
Kanamori, A1
Yamauchi, M1
Mori, H1
Terauchi, Y1
Wu, CZ1
Pei, D1
Hsieh, AT1
Wang, K1
Lin, JD2
Lee, LH1
Chu, YM1
Hsiao, FC1
Pei, C1
Hsia, TL1
Zargar, AH1
Siraj, M1
Jawa, AA1
Hasan, M1
Mahtab, H1
Vilar, L1
Canadas, V1
Arruda, MJ1
Arahata, C1
Agra, R1
Pontes, L1
Montenegro, L1
Vilar, CF1
Silva, LM1
Albuquerque, JL1
Gusmão, A1
Filozof, C1
Gautier, JF1
de Galan, B1
Onuchin, SG2
Elsukova, OS2
Solov'ev, OV2
Onuchina, EL2
Hu, YY1
Ye, SD1
Zhao, LL1
Zheng, M1
Wu, FZ1
Yang, X1
So, WY1
Ma, RC1
Yu, LW1
Ko, GT1
Kong, AP1
Ng, VW1
Luk, AO1
Ozaki, R1
Tong, PC1
Chow, CC2
Chan, JC1
Chen, LL2
Liao, YF2
Zeng, TS2
Li, HQ1
Kristiansen, SB1
Løfgren, B1
Nielsen, JM1
Støttrup, NB1
Buhl, ES1
Nielsen-Kudsk, JE1
Nielsen, TT1
Rungby, J2
Flyvbjerg, A1
Bøtker, HE1
Batty, GD1
Czernichow, S1
Huxley, R1
Harrap, SB1
Louro, TM1
Matafome, PN1
Nunes, EC1
da Cunha, FX1
Seiça, RM1
Zhang, H2
Bu, P1
Xie, YH1
Luo, J1
Lei, MX1
Mo, ZH1
Liao, EY1
Li, YM1
Ding, HC1
Boyle, JG1
Logan, PJ1
Small, M1
Sattar, N1
Connell, JM1
Cleland, SJ1
Salt, IP1
Stefansdottir, G1
Knol, MJ1
Leufkens, HG1
De Bruin, ML1
Hanif, W1
Malik, W1
Kamal, A1
Geransar, P1
Lister, N1
Andrews, C1
Barnett, A1
Thethy, I1
Robertson, L1
Swaminathan, K1
Matsuda, R1
Anguizola, J1
Joseph, KS1
Hage, DS1
Hasenbank, SE1
Brocks, DR1
Light, PE2
Saharan, VA1
Choudhury, PK1
Januszewicz, A1
Tandon, N1
Joshi, P1
Al-Azzam, SI1
Alomari, M1
Khader, YS1
Almahasneh, FA1
Muflih, SM1
Altawalbeh, S1
Gupta, PS1
Green, AN1
Jermendy, G1
Lang, VY1
Fatehi, M1
Javorsky, M1
Klimcakova, L1
Schroner, Z1
Zidzik, J1
Babjakova, E1
Fabianova, M1
Kozarova, M1
Tkacova, R1
Salagovic, J1
Tkac, I1
Lim, PC1
Lim, SL1
Oiyammaal, C1
Ragia, G1
Tavridou, A1
Petridis, I1
Manolopoulos, VG1
Magnusson, NE1
Dyrskjøt, L1
Grimm, D1
Wehland, M1
Pietsch, J1
Juurlink, DN1
Gomes, T1
Shah, BR1
Mamdani, MM1
Drews, G1
Düfer, M1
Kubo, K1
Fava, D1
Cassone-Faldetta, M1
Laurenti, O1
De Luca, O1
Ghiselli, A1
De Mattia, G1
Matsumoto, K3
Sera, Y2
Abe, Y2
Tominaga, T2
Ueki, Y1
Miyake, S2
Frey, N2
Laveille, C2
Paraire, M1
Francillard, M1
Holford, NH1
Jochemsen, R2
Bahadori, B1
Trinker, M1
Wallner, SJ1
Yazdani-Biuki, B1
Wascher, TC2
Banerjee, S1
Sinharoy, K1
Zhu, XX1
Shi, HL1
Yang, WY2
Jiang, J1
Sun, XC1
Davies, C1
Chow, WH1
Stefanović, V2
Antić, S2
Mitić-Zlatković, M1
Stojiljković, S1
Milojković, M2
Bogicević, M1
Vlahović, P2
Dhindsa, P1
Davis, KR1
Donnelly, R1
Schernthaner, G5
Starkey, BJ1
Powell, RJ1
Gribble, FM1
Clark, PM1
Hattersley, AT1
Ramachandran, A1
Furlong, NJ1
Hulme, SA1
O'Brien, SV1
Hardy, KJ1
Scheen, AJ1
Lawrence, JM1
Reid, J1
Taylor, GJ1
Stirling, C1
Reckless, JP1
Yanagawa, T1
Araki, A1
Sasamoto, K1
Shirabe, S1
Yamanouchi, T2
Guillausseau, PJ4
Campbell, IW1
Yeki, Y1
Crawford, BA1
Perera, C1
Baksi, A2
James, RE1
Zhou, B1
Nolan, JJ1
Grimaldi, A1
Di Mario, U1
Drzewoski, J3
Kempler, P1
Kvapil, M1
Novials, A1
Rottiers, R1
Rutten, GE1
Shaw, KM2
Gao, Y1
Yuan, SY1
Xing, XY1
Guo, XH1
Li, HB1
Miwa, S1
Watada, H1
Ohmura, C1
Tanaka, Y1
Kawamori, R1
Drouin, P2
Standl, E1
Stalder, Dde M1
Belcher, G3
Lambert, C2
Goh, KL1
Edwards, G4
Valbuena, M1
Gavrilă, L1
Brădescu, OM1
Guja, C1
Singhal, P1
Caumo, A1
Cobelli, C1
Taylor, R3
Katakami, N1
Yamasaki, Y1
Hayaishi-Okano, R1
Ohtoshi, K1
Kaneto, H1
Matsuhisa, M1
Kosugi, K1
Hori, M1
Khan, M1
Xu, Y1
Urquhart, R6
Boes, U1
Tan, MH2
Krahulec, B1
Kubalski, P1
Stankiewicz, A1
Johns, D2
Charbonnel, B2
Mihm, M1
Widel, M1
Tan, M1
Emral, R1
Köseoğlulari, O1
Tonyukuk, V1
Uysal, AR1
Kamel, N1
Corapçioğlu, D1
Charbonnel, BH1
Hanefeld, M2
Brunetti, P4
Hartsleben, ChH1
Battegay, E1
Schumm-Draeger, PM1
Inukai, K1
Watanabe, M1
Nakashima, Y1
Sawa, T1
Takata, N1
Tanaka, M1
Kashiwabara, H1
Yokota, K1
Suzuki, M1
Kurihara, S1
Awata, T2
Katayama, S2
Satoh, J1
Takahashi, K2
Takizawa, Y1
Ishihara, H1
Hirai, M1
Katagiri, H1
Hinokio, Y1
Suzuki, S2
Tsuji, I1
Oka, Y1
Whitelaw, D1
Kardas, P1
Betteridge, DJ1
Vergès, B1
Ning, G1
Gao, X1
Yang, HZ1
Li, M1
Hong, J1
Lu, ZQ1
Qi, YQ1
Li, ZW1
Xiang, KS1
Lu, CH1
Chang, CC1
Chuang, LM1
Wang, CY2
Jiang, YD1
Wu, HP1
Perriello, G2
Pampanelli, S2
Di Pietro, C2
de Winter, W1
DeJongh, J1
Post, T1
Ploeger, B1
Moules, I1
Eckland, D1
Danhof, M1
Pan, NH1
Lee, TM1
Lin, MS1
Huang, CL1
Chang, NC1
Ceriello, A2
Lazarević, G1
Brown, N1
Ristic, S2
Collober-Maugeais, C2
Pecher, E2
Cressier, F2
Papanas, N1
Tziakas, D1
Chalikias, G1
Floros, D1
Trypsianis, G1
Papadopoulou, E1
Kortsaris, A1
Symeonidis, G1
Souliou, E1
Maltezos, E1
Hatseras, D1
Xue, J1
Liu, M1
Chen, JH1
Zurawska-Klis, M1
Liu, X1
Kuang, H1
Yi, R1
Lemenuel-Diot, A1
Mallet, A1
Räkel, A1
Renier, G3
Roussin, A1
Buithieu, J1
Mamputu, JC1
Serri, O3
Barchielli, A1
Masotti, G1
Buiatti, E1
Mendes, GD1
Moreira, LD1
Pereira, Ados S1
Borges, A1
Yui, F1
Mendes, FD1
de Nucci, G1
Lei, WY1
Wang, TE1
Chen, TL1
Chang, WH1
Yang, TL1
Tang, P1
Bilinska, M1
Potocka, J1
Korzeniowska-Kubacka, I1
Piotrowicz, R1
Khanolkar, MP1
Morris, RH1
Thomas, AW1
Bolusani, H1
Roberts, AW1
Geen, J1
Jackson, SK1
Evans, LM1
Sena, CM1
Louro, T1
Matafome, P1
Nunes, E1
Monteiro, P1
Seiça, R1
Sliwinska, A1
Blasiak, J1
Kasznicki, J1
Barnett, AH2
Krentz, AJ1
Strojek, K3
Sieradzki, J1
Azizi, F1
Embong, M1
Imamoglu, S1
Perusicová, J1
Uliciansky, V1
Lesobre, B9
Sullivan, JT1
Smith, RB1
Golay, A1
Broquet, C1
Chabot, V1
Studer, S1
Felber, JP1
Brogard, JM1
Pinget, M1
Dorner, M1
Almér, LO1
Minami, N1
Ikeda, Y1
Abe, M1
Baba, S1
Nakagawa, S1
Takebe, K1
Goto, Y1
Maezawa, H1
Takeda, R1
Sakamoto, N2
Fukui, I1
Velikov, VK1
Shubina, IO1
Saltykov, BB1
Frolova, AI1
Robb, GH1
Lowe, SM1
Tsang, LW1
Sorensen, JP1
Cockram, CS1
Lunetta, M1
Di Mauro, M1
Crimi, S1
Mughini, L1
Sener, A1
Akkan, AG1
Malaisse, WJ1
Kumar, S1
Keswani, P1
Bose, BS1
Agrawal, JK1
Palmer, KJ1
Brogden, RN1
Akazawa, S1
Abiru, N1
Yano, M1
Ishibasi, M1
Uotani, S1
Matsuo, H1
Kawasaki, E1
Yamasaki, H1
Yamamoto, H1
Alberti, KG2
Vestergaard, H3
Weinreb, JE1
Rosen, AS1
Bjørbaek, C2
Hansen, L1
Pedersen, O4
Kahn, BB1
Tessier, D2
Dawson, K1
Tétrault, JP1
Bravo, G1
Meneilly, GS1
Sobenin, IA1
Maksumova, MA1
Slavina, ES1
Balabolkin, MI4
Orekhov, AN1
Seshiah, V1
Venkataraman, S1
Suresh, K1
Kamikubo, K1
Takami, R1
Suwa, T1
Sugiyama, A1
Horibe, N1
Sakata, S1
Wolffenbuttel, BH2
Nijst, L1
Sels, JP1
Menheere, PP1
Müller, PG1
Kruseman, AC1
Quatraro, A2
De Rosa, N1
Acampora, R1
Giugliano, D2
Chen, KW1
Juang, JH1
Huang, HS1
Huang, BY1
Huang, MJ1
Bresler, M1
Gumprecht, J1
Grzeszczak, W2
Trautsolt, W1
Wajchenberg, BL2
Santomauro, AT2
Porrelli, RN2
Zapecka-Dubno, B1
Wiśniewska, K1
Szczepanik, Z1
Kasperska-Czyzykowa, T1
Rupprecht, E1
König, E1
Limmer, J1
Tsumura, K1
Ogata, N1
Tagaya, T1
Kawasaki, T1
Sekino, N1
Funato, H1
Akaoka, L1
Miyashita, H1
Lund, S1
Yoshioka, K1
Riccio, A1
Lisato, G1
de Kreutzenberg, SV1
Marchetto, S2
Turrin, M1
Tiengo, A3
Del Prato, S2
Braatvedt, GD1
Inoue, I1
Noji, S1
Negishi, K1
Gregorio, F2
Ambrosi, F2
Manfrini, S2
Santucci, A1
Filipponi, P2
Rachman, J1
Levy, JC1
Barrow, BA1
Manley, SE2
Turner, RC4
Kaneko, T1
Boland, O1
O'Brien, RC1
Luo, M1
Cathelineau, G1
de Champvallins, M1
Bouallouche, A1
Hammersley, MS2
Meyer, LC1
Morris, RJ2
Holman, RR2
Karunakaran, S1
Rabbone, I1
Piccinini, M1
Curto, M1
Mostert, M1
Gamba, S1
Mioletti, S1
Bruno, R1
Rinaudo, MT1
Desfaits, AC2
Bardini, G1
Rotella, CM1
Dachicourt, N1
Bailbé, D2
Gangnerau, MN1
Serradas, P3
Ravel, D1
Portha, B3
Muggeo, M1
Galeone, F2
Fiore, G2
Arcangeli, A1
Elhadd, TA1
Newton, RW1
Jennings, PE6
Belch, JJ4
Ammari, F1
Koppiker, N1
Gregory, R1
Burden, AC1
Maheux, P1
Khalil, A1
Fülöp, T1
Güvener, N1
Gedik, O1
Dourakis, SP1
Tzemanakis, E1
Sinani, C1
Kafiri, G1
Hadziyannis, SJ1
Velussi, M1
Carle, F1
Testa, R1
Merante, D1
Gomis, R1
Squatrito, S1
Jones, NP1
Patwardhan, RN1
Tzanakis, N1
Bouros, D1
Siafakas, N1
Davis, TM1
Daly, F1
Walsh, JP1
Ilett, KF1
Beilby, JP1
Dusci, LJ1
Barrett, PH1
Tripathi, BK1
Gougeon, R1
Styhler, K1
Morais, JA1
Jones, PJ1
Marliss, EB1
de Smet, PA1
Fischer, HR1
Kihara, Y1
Otsuki, M1
Paroni, R1
Comuzzi, B1
Arcelloni, C1
Brocco, S1
de Kreutzenberg, S1
Ciucci, A1
Beck-Peccoz, P1
Genovese, S1
Cerasi, E4
Harrower, A1
Crepaldi, G1
Fioretto, P1
Alagözlü, H1
Gültekin, F1
Candan, F1
Chazan, AC1
Gomes, MB1
Shustov, SB1
Romashevskiĭ, BV1
Khalimov, IuSh1
Stepanova, OIu1
Lysenko, AG1
Salman, S1
Salman, F1
Yilmaz, Y1
Ozer, E1
Sengül, A1
Demirel, HO1
Karşidağ, K1
Dinççağ, N1
Yilmaz, MT1
van der Wal, PS1
Heine, RJ1
Spallarossa, P1
Schiavo, M1
Rossettin, P1
Cordone, S1
Olivotti, L1
Cordera, R1
Brunelli, C1
Greb, W1
da Tos, V1
Maran, A1
Vigili de Kreutzenberg, S1
Tadiotto, F1
Bettio, M1
Marescotti, MC1
Ligtenberg, JJ1
Reitsma, WD1
van Haeften, TW1
Juhl, CB1
Pørksen, N1
Pincus, SM1
Hansen , AP1
Veldhuis, JD1
Schmitz, O2
Bratholm, P1
Christensen, NJ1
Chugh, SN1
Dhawan, R1
Kishore, K1
Sharma, A1
Chugh, K1
McGavin, JK1
Perry, CM1
Goa, KL1
Cho, YW1
Oh, DY1
Baick, SH1
Kim, SK1
Kim, SJ1
Hong, SY1
Pugh, JA1
Wagner, ML1
Sawyer, J1
Ramirez, G1
Tuley, M1
Friedberg, SJ1
Giannella-Neto, D1
Borghi, VC1
Aschner, P1
Kattah, W1
Roblin, X1
Abinader, Y1
Baziz, A1
Phenekos, C1
Siafaka-Kapadai, A1
Trapali, M1
Botitsi, E1
Mavris, M1
Fu, ZZ1
Yan, T1
Chen, YJ1
Sang, JQ1
Scott, NA1
Saniabadi, AR1
Johnson, AB2
Krall, LP1
Campbell, DB2
Lavielle, R2
Nathan, C1
Chiasson, JL1
Verdy, M1
Hosker, JP2
Stratton, I1
Bak, JF2
Harrower, AD3
Della Casa, L2
del Rio, G2
Glaser, B2
Kilo, C1
Dudley, J1
Kalb, B1
Ziegler, O1
Argyraki, M1
Thow, JC1
Jones, IR1
Broughton, D1
Miller, M1
Kawai, K1
Murayama, Y1
Watanabe, Y1
Yamashita, K1
Colwell, JA1
Rifkin, H1
Marquié, G1
Hadjiisky, P1
Arnaud, O1
Duhault, J1
Akanuma, Y2
Kosaka, K2
Kanazawa, Y2
Kasuga, M2
Fukuda, M2
Aoki, S2
Gram, J2
Jespersen, J2
Noury, J1
Nandeuil, A1
Monges, AM1
Pisano, P1
Aujoulat, P1
Salducci, D1
Durand, A1
Panagides, D1
Bory, M1
Crevat, A1
Wong, C1
Chang, TC1
Wang, LM1
Cheng, CY1
Kuo, HF1
Liu, PC1
Ho, LT1
Batch, J1
Ma, A2
Bird, D2
Noble, R1
Charles, B1
Ravenscroft, P1
Cameron, D1
Ishibashi, F1
Takashina, S1
Kozlov, GS1
Buĭdina, TA1
Kold, A1
Sørensen, NS1
Rudenski, AS1
Burnett, MA1
Kamp, M1
Howlett, V1
Cameron, DP1
Conget, JI1
Vendrell, J1
Esmatjes, E1
Halperin, I1
Paterson, KR1
Gyi, KM1
McBride, D1
Cohen, HN1
Shenkin, A1
Manderson, WG1
MacCuish, AC1
Wheeley, MS1
Ward, JD1
Procacci, V1
Giovine, A1
Roberto, MG1
Di Reda, N1
Lasorsa, G1
Vendemiale, G1
Stufano, N1
Altomare, E1
Wajchenberg, BJ1
Santomaruo, AT1
Cherem, JJ1
Malerbi, DA1
Giurno Filho, A1
Lerario, AC1
Giannella Neto, D1
Larkins, RG1
Jerums, G1
Taft, JL1
Godfrey, H1
Smith, IL1
Martin, TJ1
Cortinovis, A1
Crippa, A1
Sciacca, V1
Caravaggio, V1
Crippa, M1
Florkowski, CM1
Richardson, MR1
Le Guen, C1
O'Donnell, MJ1
Jones, AF1
Lunec, J1
Nedosugova, LV1
Giraudo, JR1
Fugante, M1
Blaque Quadri, J1
Reyes, G1
Duran Saucedo, N1
McAlpine, LG1
McAlpine, CH1
Waclawski, ER1
Storer, AM1
Kay, JW1
Frier, BM1
Morozova, TP1
Chachiashvili, MV1
Frühwald, T1
Böhmer, F1
Patel, JC1
Vikani, AV1
Svoboda, Z1
Consoli, G1
Zurro Hernandez, J1
Ward, G1
Harrison, LC1
Proietto, J1
Aitken, P1
Nankervis, A1
Donatelli, M1
Sinagra, D1
Russo, V1
Bucalo, ML1
Giardina, E1
Cerasola, GA1
Bompiani, G1
Delargy, M1
McGovern, M1
Johnson, A1
Tomkin, GH1

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790]Phase 4119 participants (Actual)Interventional2018-10-02Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]8,494 participants (Actual)Observational2010-01-31Completed
A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus[NCT02682563]Phase 444 participants (Actual)Interventional2016-02-29Completed
Study of Sulphonylurea Synergy With Incretins[NCT03705195]20 participants (Actual)Interventional2018-08-03Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]150 participants (Anticipated)Interventional2016-11-30Active, not recruiting
A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan[NCT01758380]Phase 4557 participants (Actual)Interventional2013-01-31Completed
Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus[NCT00736515]Phase 4160 participants (Actual)Interventional2008-10-31Completed
A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Ty[NCT01709305]Phase 45,570 participants (Actual)Interventional2012-11-08Completed
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]200 participants (Anticipated)Observational2012-01-31Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]160 participants (Actual)Interventional2013-12-31Active, not recruiting
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]Phase 4135 participants (Actual)Interventional2016-10-31Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]Phase 3104 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]465 participants (Actual)Interventional2015-08-31Completed
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]Phase 4102 participants (Actual)Interventional2012-08-31Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]Phase 220 participants (Actual)Interventional2014-04-30Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]0 participants (Actual)Interventional2011-09-30Withdrawn
Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose- A Double-blind, Placebo-controlled Clinical Research[NCT05737342]80 participants (Anticipated)Interventional2023-04-01Not yet recruiting
Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes[NCT00102388]Phase 31,092 participants (Actual)Interventional2005-01-31Completed
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445]Phase 477 participants (Actual)Interventional2008-11-30Completed
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213]Phase 460 participants (Actual)Interventional2012-09-30Completed
Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes[NCT01238380]1,916 participants (Actual)Observational2010-12-31Completed
Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597]Phase 330 participants (Actual)Interventional2008-04-30Completed
Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359]138 participants (Anticipated)Observational [Patient Registry]2019-05-06Recruiting
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692]Phase 3500 participants (Anticipated)Interventional2021-08-31Suspended (stopped due to Administrative decision of the investigation direction)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Body Weight

Measured in kilograms (NCT02682563)
Timeframe: 12 weeks

Interventionkilograms (Mean)
Dapagliflozin 10mg Once Daily93.7
Gliclazide Modified Release 30mg Once Daily99.6

Effective Renal Plasma Flow (ERPF) in ml/Min

Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min (NCT02682563)
Timeframe: 12 weeks

Interventionml/min (Mean)
Dapagliflozin 10mg Once Daily639
Gliclazide Modified Release 30mg Once Daily678

Fractional Excretion of Glucose in % of Filtered Glucose

Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose (NCT02682563)
Timeframe: 12 weeks

Intervention% of filtered glucose (Mean)
Dapagliflozin 10mg Once Daily31.1
Gliclazide Modified Release 30mg Once Daily0.6

Fractional Excretion of Potassium in % of Filtered Potassium

Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium (NCT02682563)
Timeframe: 12 weeks

Intervention% of filtered potassium (Mean)
Dapagliflozin 10mg Once Daily13.6
Gliclazide Modified Release 30mg Once Daily11.8

Fractional Excretion of Sodium in % of Filtered Sodium

Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium (NCT02682563)
Timeframe: 12 weeks

Intervention% of filtered sodium (Mean)
Dapagliflozin 10mg Once Daily0.74
Gliclazide Modified Release 30mg Once Daily0.66

Glomerular Filtration Rate (GFR) in ml/Min

Calculated from urinary and plasma inulin concentrations, GFR in ml/min (NCT02682563)
Timeframe: 12 weeks

Interventionml/min (Mean)
Dapagliflozin 10mg Once Daily104
Gliclazide Modified Release 30mg Once Daily109

Kidney Injury Molecule-1 (KIM-1) in ng/mmol

KIM-1 (ng/mmol) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks

Interventionng/mmol (Median)
Dapagliflozin 10mg Once Daily0.25
Gliclazide Modified Release 30mg Once Daily0.265

Neutrophil Gelatinase-associated Lipocalin (NGAL)

NGAL (ng/mmoll) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks

Interventionng/mmol (Median)
Dapagliflozin 10mg Once Daily3.76
Gliclazide Modified Release 30mg Once Daily3.79

Systolic Blood Pressure

Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg (NCT02682563)
Timeframe: 12 weeks

InterventionmmHg (Mean)
Dapagliflozin 10mg Once Daily129.2
Gliclazide Modified Release 30mg Once Daily131.1

Urinary Albumin-Creatinine Ratio in mg/mmol

Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol (NCT02682563)
Timeframe: 12 weeks

Interventionmg/mmol (Median)
Dapagliflozin 10mg Once Daily0.88
Gliclazide Modified Release 30mg Once Daily0.54

Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)

HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20) and Week 44

InterventionPercent (Least Squares Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride-0.65
Phase 2: Metformin + Sitagliptin + Repaglinide-0.62
Phase 2: Metformin + Sitagliptin + Acarbose-0.46
Phase 2: Metformin + Sitagliptin + Gliclazide-0.69

Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)

Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20), Week 44

Interventionkg (Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride0.4
Phase 2: Metformin + Sitagliptin + Repaglinide0.2
Phase 2: Metformin + Sitagliptin + Acarbose-0.9
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)

"The percentage of participants with a GI AE of nausea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)

"The percentage of participants with a GI AE of abdominal pain was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With a GI AE of Diarrhea (Phase 2)

"The percentage of participants with a GI AE of diarrhea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.5
Phase 2: Metformin + Sitagliptin + Repaglinide0.4
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.9

Percentage of Participants With a GI AE of Vomiting (Phase 2)

"The percentage of participants with a GI AE of vomiting was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.2
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.2
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With Hypoglycemia Events (Phase 2)

Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported. (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride8.9
Phase 2: Metformin + Sitagliptin + Repaglinide6.1
Phase 2: Metformin + Sitagliptin + Acarbose0.5
Phase 2: Metformin + Sitagliptin + Gliclazide3.6

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

Interventionpercentage (Mean)
Insulin Glargine, Metformin, Exenatide-2.43
Insulin Glargine, Metformin, Prandial Insulin0.44

HbA1C Levels

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Intervention% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide7.1
Insulin Glargine, Metformin, Prandial Insulin7.2

Number of Participants With Hypoglycemia

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

InterventionParticipants (Count of Participants)
Insulin Glargine, Metformin, Exenatide0
Insulin Glargine, Metformin, Prandial Insulin0

Weight Change During Trial

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Interventionkg (Mean)
Insulin Glargine, Metformin, Exenatide-4.8
Insulin Glargine, Metformin, Prandial Insulin0.7

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

Interventionµg/ml (Median)
Sitagliptin0
Gliclazide8.4

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

Interventionmmol/L (Median)
Sitagliptin-0.2
Gliclazide-0.1

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

InterventionmmHg (Median)
Sitagliptin4
Gliclazide-9

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

Interventionmmol/L (Median)
Sitagliptin0.1
Gliclazide-0.1

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

Interventionscore on a scale (Median)
Sitagliptin3
Gliclazide1.8

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

Interventionscore on a scale (Median)
Sitagliptin9.5
Gliclazide9.4

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

Interventionkg (Median)
Sitagliptin-0.5
Gliclazide-0.6

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

InterventiondCt (Median)
Gliclazide-1.12
Sitagliptin0

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

InterventiondCt (Median)
Sitagliptin3.41
Gliclazide2.09

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin-0.07
Gliclazide0.43

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

InterventionParticipants (Count of Participants)
Sitagliptin6
Gliclazide10

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

,
Interventionscore on a scale (Median)
DLQIHAQ-8HADS AnxietyHADS DepressionEQ-5D
Gliclazide-1.00.000-0.2
Sitagliptin0.00.0-100

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

,
InterventionParticipants (Count of Participants)
PASI 50PASI 75PASI 90
Gliclazide100
Sitagliptin100

Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmmol/l (Mean)
Baseline FSG3rd Month FSG
Metformin ( 002 Group)6.26.5
Pioglitazone (001 Group)6.95.4

Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionμU/ml (Mean)
Baseline FSI3rd month FSI
Metformin ( 002 Group)13.013.9
Pioglitazone (001 Group)16.212.3

Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HbA1c3rd month HbA1c
Metformin ( 002 Group)7.87.0
Pioglitazone (001 Group)7.36.7

Comparison of Changes in HOMA Percent B and HOMA Percent S With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HOMA percent beta cells function3rd month HOMA percent beta cells functionBaseline HOMA percent sensitivity3rd month HOMA percent sensitivity
Metformin ( 002 Group)109.3116.076.267.2
Pioglitazone (001 Group)118.9132.351.169.3

Comparison of Changes in Insulin Levels (HOMA IR,QUICKI) With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionScore on a scale ( SI unit) (Mean)
Baseline QUICKI3rd month QUICKIBaseline HOMA IR3rd month HOMA IR
Metformin ( 002 Group)0.570.543.74.3
Pioglitazone (001 Group)0.520.595.12.9

Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmg/dl (Mean)
Baseline TC3rd month TCBaseline TG3rd month TGBaseline HDL3rd month HDLBaseline LDL3rd month LDL
Metformin (002 Group)193.0177.0166.0175.034.434.7125.6112.0
Pioglitazone (001 Group)182.01781831953333.2112.8105.5

Cholesterol Efflux Capacity of HDL

The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks

InterventionRatio (Mean)
Pioglitazone Group1.02
Comparator Group1.05

HDL Apolipoprotein Levels at Study End-point

Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks

,
Interventionmg/dL (Mean)
HDL-apoAI at end pointHDL-apoAII at end pointHDL-apoCI at end pointHDL-apoCII at end pointHDL-apoCIII at end pointHDL-apoM at end point
Comparator Group65.722.68.42.812.50.43
Pioglitazone Group65.026.610.93.511.80.62

Increased HDL-Cholesterol and Decreased Triglycerides

"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks

,
Intervention% Change (Mean)
% Change in HDL cholesterol at 12 weeks% Change in HDL cholesterol at 24 weeks% Change in triglycerides at 12 weeks% Change in triglycerides at 24 weeks
Comparator Group2.7-1.57.419.7
Pioglitazone Group7.915.7-10.9-15.4

Reviews

50 reviews available for gliclazide and Diabetes Mellitus, Adult-Onset

ArticleYear
Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:17

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Comp

2022
ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release.
    Diabetes, obesity & metabolism, 2020, Volume: 22 Suppl 2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Feasibility Studies; Gliclazide; Glycemic Control; Humans;

2020
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Diabetes research and clinical practice, 2018, Volume: 143

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2018
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Rela

2019
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
    Current diabetes reviews, 2013, Volume: 9, Issue:5

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ

2013
Liuwei dihuang pills enhance the effect of Western medicine in treating type 2 diabetes: A meta-analysis of randomized controlled trials.
    Chinese journal of integrative medicine, 2013, Volume: 19, Issue:10

    Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Fasting; Glic

2013
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2

2014
[Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].
    Orvosi hetilap, 2015, Mar-29, Volume: 156, Issue:13

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gliclazide; Humans; Hu

2015
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Diabetes research and clinical practice, 2015, Volume: 109, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gliclazide; H

2015
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Diabetes research and clinical practice, 2015, Volume: 110, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glicl

2015
Is gliclazide a sulfonylurea with difference? A review in 2016.
    Expert review of clinical pharmacology, 2016, Volume: 9, Issue:6

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Prac

2016
Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development.
    Current medicinal chemistry, 2018, Volume: 25, Issue:39

    Topics: Biological Products; Diabetes Mellitus, Type 2; Drug Discovery; Gliclazide; Glucose Transporter Type

2018
Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature.
    Endocrine, metabolic & immune disorders drug targets, 2016, Volume: 16, Issue:4

    Topics: Acarbose; Aged; Autoimmune Diseases; Diabetes Mellitus, Type 2; Drug Substitution; Gliclazide; Human

2016
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:2

    Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe

2012
[Hypoglycemia].
    Praxis, 2011, Oct-19, Volume: 100, Issue:21

    Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans;

2011
[Incretin-based therapy for treating patients with type 2 diabetes].
    Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48

    Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibito

2011
Treating diabetes today with gliclazide MR: a matter of numbers.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 1

    Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne

2012
Role of K(ATP) channels in β-cell resistance to oxidative stress.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 3

    Topics: Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation, Enzymologic

2012
Oral hypoglycaemic agent failure.
    Journal of the Indian Medical Association, 2002, Volume: 100, Issue:7

    Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glycated Hem

2002
Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.
    Metabolism: clinical and experimental, 2003, Volume: 52, Issue:8 Suppl 1

    Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration S

2003
[Medication of the month. Gliclazide modified release (Uni Diamicron)].
    Revue medicale de Liege, 2003, Volume: 58, Issue:10

    Topics: Administration, Oral; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hy

2003
Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.
    International journal of clinical practice, 2004, Volume: 58, Issue:2

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Metfo

2004
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
    International journal of clinical practice, 2004, Volume: 58, Issue:9

    Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl

2004
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
    Diabetologia, 2005, Volume: 48, Issue:3

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Me

2005
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
    MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli

2005
Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2

    Topics: Adult; Aged; Asian People; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Do

2006
Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis.
    Journal of pharmacokinetics and pharmacodynamics, 2007, Volume: 34, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Likelihood Functi

2007
New insights from ADVANCE.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2007, Volume: 25, Issue:1

    Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus, T

2007
[Diabetic retinopathy. Effects of gliclazide].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1983

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans; Sulfo

1983
[Non-insulin dependent diabetes. Role of gliclazide (diamicron)].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1995

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gliclazide; Humans; Male

1995
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
    Drugs, 1993, Volume: 46, Issue:1

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Drug

1993
[Gliclazide: review of metabolic and vascular action].
    Diabete & metabolisme, 1994, Volume: 20, Issue:3 Pt 2

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Gliclazide; Glucose; Humans

1994
[Clinical efficacy of glimepiride].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55 Suppl

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Insuli

1997
[Timing of administration of sulfonyl urea derivatives].
    Nederlands tijdschrift voor geneeskunde, 2000, Jun-17, Volume: 144, Issue:25

    Topics: Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administr

2000
Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Suppl 2

    Topics: ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hyp

2000
Vascular benefits of gliclazide beyond glycemic control.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Suppl 2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Glic

2000
Gliclazide modified release: its place in the therapeutic armamentarium.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Suppl 2

    Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Secretion; Islets

2000
Gliclazide modified release.
    Drugs, 2002, Volume: 62, Issue:9

    Topics: Animals; Biological Availability; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Gliclazide

2002
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
    Diabetes care, 1992, Volume: 15, Issue:8

    Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glic

1992
Gliclazide: metabolic and vascular effects--a perspective.
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Insul

1992
The treatment of NIDDM in the decade of the 90s.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Diabetes Mellitus, Type 2; Diet, Diabetic; Forecasting; Gliclazide; Humans; Insulin; Sulfonylurea Co

1991
The mode of action and clinical pharmacology of gliclazide: a review.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Adult; Aged; Animals; Diabetes Mellitus, Type 2; Gliclazide; Humans; Islets of Langerhans; Platelet

1991
Gliclazide and insulin action in human muscle.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Animals; Diabetes Mellitus, Type 2; Gliclazide; Glycogen; Humans; Insulin; Muscles

1991
Hemobiological activity of gliclazide in diabetes mellitus.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Platelet Adhe

1991
Current status of non-insulin-dependent diabetes mellitus (type II): management with gliclazide.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Exercise; Gliclazide; Humans; Insulin

1991
[Glycogen synthetase and non-insulin-dependent diabetes: role of gliclazide].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1991

    Topics: Biopsy; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gliclazide; Glycogen Synthase; Humans;

1991
[Macroangiopathy and type 2 diabetes mellitus: significance of Diamicron].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1990

    Topics: Animals; Arteriosclerosis; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endoth

1990
[Physiopathology of non insulin-dependent diabetes. Action of gliclazide].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1985

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Resistance; Insulin Secretion

1985
[Diamicron through the European Association for the Study of Diabetes and the International Diabetes Federation congresses in Sydney in 1988].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1989

    Topics: Animals; Australia; Diabetes Mellitus, Type 2; Gliclazide; Humans; Paris; Rats; Sulfonylurea Compoun

1989
[Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1988

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; In

1988

Trials

157 trials available for gliclazide and Diabetes Mellitus, Adult-Onset

ArticleYear
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
    Canadian journal of diabetes, 2022, Volume: 46, Issue:5

    Topics: Adult; Aged; Biosimilar Pharmaceuticals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations

2022
Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors.
    Clinical journal of the American Society of Nephrology : CJASN, 2022, Volume: 17, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hyperkalemi

2022
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
    The Journal of clinical endocrinology and metabolism, 2020, 01-01, Volume: 105, Issue:1

    Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin

2020
Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:4

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2;

2020
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    Kidney international, 2020, Volume: 97, Issue:1

    Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method;

2020
Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
    Diabetes & metabolism, 2020, Volume: 46, Issue:2

    Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fe

2020
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Diabetes care, 2020, Volume: 43, Issue:6

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2

2020
Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
    Journal of hypertension, 2020, Volume: 38, Issue:9

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Gliclazide; Glomerular Filtration Rate; Glucosides;

2020
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    Clinical science (London, England : 1979), 2020, 12-11, Volume: 134, Issue:23

    Topics: Acid-Base Equilibrium; Ammonium Compounds; Benzhydryl Compounds; Bicarbonates; Blood Glucose; Citrat

2020
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
    Journal of diabetes, 2017, Volume: 9, Issue:8

    Topics: Adipose Tissue; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyc

2017
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    Diabetologia, 2018, Volume: 61, Issue:4

    Topics: Aged; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations;

2018
Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2019, Volume: 127, Issue:4

    Topics: Aged; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Female; Gliclazide; Glycated Hemoglob

2019
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2
    Diabetes research and clinical practice, 2018, Volume: 139

    Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Brazil; Delayed-Action Prepar

2018
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
    Journal of diabetes investigation, 2019, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Fem

2019
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:8

    Topics: Aged; Antihypertensive Agents; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy,

2019
Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
    Scientific reports, 2019, 06-12, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Glicla

2019
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T

2014
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
    Diabetes care, 2014, Volume: 37, Issue:5

    Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabet

2014
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Current medical research and opinion, 2014, Volume: 30, Issue:7

    Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2014
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014, Volume: 122, Issue:5

    Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogly

2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat

2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat

2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat

2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat

2014
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Vascular health and risk management, 2014, Volume: 10

    Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dip

2014
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
    The New England journal of medicine, 2014, Oct-09, Volume: 371, Issue:15

    Topics: Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow

2014
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:1

    Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell

2015
Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
    Diabetes/metabolism research and reviews, 2015, Volume: 31, Issue:7

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; China; Diabetes Mellitus, Type 2; Drug Therapy, Combin

2015
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:5

    Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combin

2015
Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation.
    Diabetes research and clinical practice, 2016, Volume: 112

    Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Respons

2016
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Current medical research and opinion, 2016, Volume: 32, Issue:6

    Topics: Adamantane; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Dipepti

2016
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
    Diabetes care, 2016, Volume: 39, Issue:5

    Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin

2016
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
    Diabetes care, 2016, Volume: 39, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F

2016
Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus.
    The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:10

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Comorbidity; Cross-Over Studies; Diabetes Mellitus, Typ

2016
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    Journal of diabetes science and technology, 2017, Volume: 11, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Eld

2017
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
    Diabetes care, 2016, Volume: 39, Issue:12

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea

2016
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.
    Acta pharmacologica Sinica, 2017, Volume: 38, Issue:1

    Topics: Alleles; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Female; Genotype; Gliclazide

2017
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Science China. Life sciences, 2017, Volume: 60, Issue:3

    Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe

2017
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes.
    Diabetes technology & therapeutics, 2008, Volume: 10, Issue:5

    Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female

2008
Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Geriatrics & gerontology international, 2008, Volume: 8, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Administra

2008
Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
    Journal of internal medicine, 2009, Volume: 265, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fa

2009
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
    Diabetes care, 2009, Volume: 32, Issue:11

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose;

2009
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2009, Volume: 41, Issue:12

    Topics: Adamantane; Demography; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glicl

2009
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
    Diabetes research and clinical practice, 2010, Volume: 88, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbamates; Chi-Square Distribution; Diabetes Mell

2010
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
    Archives of pharmacal research, 2010, Volume: 33, Issue:3

    Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Cross-Over Studies; Diabetes Mell

2010
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:3

    Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase

2010
The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial.
    Diabetes research and clinical practice, 2010, Volume: 89, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agent

2010
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:8

    Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The

2010
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
    Clinical endocrinology, 2010, Volume: 73, Issue:6

    Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Chemokine CCL2; Creatinine; Cytokines; Diabetes M

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients.
    Endocrine, 2010, Volume: 38, Issue:2

    Topics: Adult; Biomarkers; Cell Movement; Cells, Cultured; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug

2010
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
    Journal of the American College of Cardiology, 2010, Nov-30, Volume: 56, Issue:23

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A

2010
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Chinese medical journal, 2011, Volume: 124, Issue:2

    Topics: Adult; Blood Glucose; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazid

2011
Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
    European journal of pharmacology, 2011, Jun-01, Volume: 659, Issue:2-3

    Topics: Adult; Antioxidants; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium, Vascu

2011
AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study.
    Diabetologia, 2011, Volume: 54, Issue:7

    Topics: Aged; AMP-Activated Protein Kinases; Cross-Over Studies; Diabetes Mellitus, Type 2; Gliclazide; Huma

2011
Intensive glucose control and risk of cancer in patients with type 2 diabetes.
    Diabetologia, 2011, Volume: 54, Issue:7

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Ins

2011
Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
    Diabetes care, 2011, Volume: 34, Issue:12

    Topics: Aged; Asia; Australia; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Euro

2011
KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
    European journal of internal medicine, 2012, Volume: 23, Issue:3

    Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination;

2012
Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:9

    Topics: Adult; Aged; Antioxidants; Arginine; Blood Pressure; Diabetes Mellitus, Type 2; Free Radicals; Glicl

2002
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
    Metabolism: clinical and experimental, 2002, Volume: 51, Issue:12

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glic

2002
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Relationship, Drug; Fem

2003
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
    Diabetes technology & therapeutics, 2003, Volume: 5, Issue:1

    Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther

2003
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:6

    Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind

2003
Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Lancet (London, England), 2003, Oct-18, Volume: 362, Issue:9392

    Topics: Adult; Aged; ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus,

2003
Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.
    Diabetes research and clinical practice, 2003, Volume: 62, Issue:1

    Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule;

2003
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Diabetic medicine : a journal of the British Diabetic Association, 2003, Volume: 20, Issue:11

    Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio

2003
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Diabetes care, 2004, Volume: 27, Issue:1

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated

2004
Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes.
    Metabolism: clinical and experimental, 2004, Volume: 53, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Cholesterol; Creatinine; Deoxyglucose; D

2004
Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea.
    Acta diabetologica, 2004, Volume: 41, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio

2004
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
    European journal of clinical investigation, 2004, Volume: 34, Issue:8

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hyp

2004
[The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
    Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:7

    Topics: Adult; Aged; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyp

2004
Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
    Endocrine journal, 2004, Volume: 51, Issue:4

    Topics: Adult; Cross-Over Studies; Cyclohexanes; Deoxyglucose; Diabetes Mellitus, Type 2; Gliclazide; Glycat

2004
Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:6

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Metho

2004
NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2004, Volume: 42, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Chole

2004
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
    Metabolism: clinical and experimental, 2005, Volume: 54, Issue:1

    Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucag

2005
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Diabetologia, 2004, Volume: 47, Issue:11

    Topics: Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem

2004
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
    International journal of clinical practice, 2004, Volume: 58, Issue:10

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;

2004
Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Clinical physiology and functional imaging, 2005, Volume: 25, Issue:1

    Topics: Adult; Analysis of Variance; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationsh

2005
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.
    Diabetes care, 2005, Volume: 28, Issue:3

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glyc

2005
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
    Diabetologia, 2005, Volume: 48, Issue:3

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Me

2005
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:4

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administ

2005
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Diabetologia, 2005, Volume: 48, Issue:6

    Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Gl

2005
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
    Diabetes research and clinical practice, 2005, Volume: 68, Issue:3

    Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe

2005
Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
    Diabetes research and clinical practice, 2005, Volume: 70, Issue:3

    Topics: Age of Onset; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glic

2005
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
    Diabetes research and clinical practice, 2005, Volume: 70, Issue:1

    Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose;

2005
Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated He

2005
The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:6

    Topics: Adult; Aged; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule;

2005
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Diabetologia, 2005, Volume: 48, Issue:12

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;

2005
[A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].
    Zhonghua yi xue za zhi, 2005, Sep-28, Volume: 85, Issue:37

    Topics: Adult; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged

2005
Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2

    Topics: Adult; Aged; Asian People; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Do

2006
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:3

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Female

2006
Association of gliclazide and left ventricular mass in type 2 diabetic patients.
    Diabetes research and clinical practice, 2006, Volume: 74, Issue:2

    Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Electrocardiography; Female; Gliclazide; Glyburide

2006
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind

2006
ADVANCE: breaking new ground in type 2 diabetes.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2006, Volume: 24, Issue:5

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics

2006
Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients.
    Diabetes & metabolism, 2006, Volume: 32, Issue:4

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Glycated Hemoglobin;

2006
Clinical observation on effect of Kaixin capsule in treating 40 patients with diabetic myocardial ischemia.
    Chinese journal of integrative medicine, 2006, Volume: 12, Issue:3

    Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Elec

2006
Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus.
    Current medical research and opinion, 2006, Volume: 22, Issue:10

    Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin

2006
Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.
    Diabetes research and clinical practice, 2007, Volume: 77, Issue:1

    Topics: Adult; ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype

2007
Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Gliclazi

2007
A bioequivalence study of gliclazide based on quantification by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:3

    Topics: Adult; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Sta

2007
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:4

    Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Femal

2007
'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
    Coronary artery disease, 2007, Volume: 18, Issue:6

    Topics: Angina Pectoris; Blood Pressure; Diabetes Mellitus, Type 2; Exercise; Gliclazide; Glyburide; Heart R

2007
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
    Atherosclerosis, 2008, Volume: 197, Issue:2

    Topics: Adult; Aged; Blood Glucose; Blood Platelets; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Gliclaz

2008
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes.
    Diabetes & vascular disease research, 2007, Volume: 4, Issue:3

    Topics: Adult; Aged; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug;

2007
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Typ

2008
[Diabetic retinopathy. Effects of gliclazide].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1983

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans; Sulfo

1983
Gliclazide: a new sulphonylurea.
    The New Zealand medical journal, 1984, Jan-11, Volume: 97, Issue:747

    Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male; Middle

1984
Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    The Tohoku journal of experimental medicine, 1983, Volume: 141 Suppl

    Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopath

1983
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Diabetes care, 1995, Volume: 18, Issue:3

    Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholestero

1995
No important differences in glycaemic responses to common fruits in type 2 diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:8

    Topics: Analysis of Variance; Bread; Citrus; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrate

1995
Insulin response after treatment depends on fasting plasma glucose level in NIDDM.
    Diabetes research and clinical practice, 1994, Dec-16, Volume: 26, Issue:2

    Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting

1994
Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
    Diabetic medicine : a journal of the British Diabetic Association, 1994, Volume: 11, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Humans; Hypoglycemia;

1994
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
    European journal of clinical pharmacology, 1993, Volume: 45, Issue:2

    Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glybur

1993
Combination therapy in NIDDM.
    Diabetes care, 1993, Volume: 16, Issue:12

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glic

1993
Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Diabetes research and clinical practice, 1995, Volume: 28 Suppl

    Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gliclazide; Glyca

1995
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
    Lancet (London, England), 1996, Jun-01, Volume: 347, Issue:9014

    Topics: Biomarkers; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Ev

1996
Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients.
    Metabolism: clinical and experimental, 1996, Volume: 45, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon;

1996
Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Diabetes research and clinical practice, 1997, Volume: 36, Issue:3

    Topics: Acarbose; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2;

1997
Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
    Diabetes research and clinical practice, 1997, Volume: 37, Issue:1

    Topics: Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2

1997
Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Diabetes, 1997, Volume: 46, Issue:10

    Topics: Adult; Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Fast

1997
The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1

    Topics: Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Respon

1997
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1

    Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St

1997
The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Fructosamin

1997
The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Gliclazide;

1997
Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia.
    Diabetic medicine : a journal of the British Diabetic Association, 1998, Volume: 15, Issue:8

    Topics: Blood Glucose; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyp

1998
[Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data].
    Minerva endocrinologica, 1998, Volume: 23, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Combinations; Female; Gliclazide; Humans; Hypoglycemic Agents; Male;

1998
The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
    Diabetic medicine : a journal of the British Diabetic Association, 1999, Volume: 16, Issue:2

    Topics: Adult; Aged; Asia, Southeastern; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic

1999
Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.
    Metabolism: clinical and experimental, 1999, Volume: 48, Issue:7

    Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Lipid

1999
Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
    Acta diabetologica, 1999, Volume: 36, Issue:1-2

    Topics: Acarbose; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellit

1999
Medium-term hypoglycaemic effects of two different oral formulations of gliclazide.
    Diabetic medicine : a journal of the British Diabetic Association, 1999, Volume: 16, Issue:7

    Topics: Adult; Aged; Blood Glucose; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Female; Gliclazide

1999
Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.
    Diabetic medicine : a journal of the British Diabetic Association, 1999, Volume: 16, Issue:12

    Topics: Aged; Aging; Antithrombin III; Blood Glucose; Blood Platelets; Cholesterol, HDL; Cholesterol, LDL; D

1999
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17, Issue:1

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mel

2000
Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:2 Suppl 1

    Topics: Adult; Aged; Blood Platelets; Collagen; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy

2000
Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.
    British journal of clinical pharmacology, 2000, Volume: 49, Issue:3

    Topics: Adult; Aged; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogl

2000
Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2001, Volume: 34, Issue:1

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug

2001
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
    Current medical research and opinion, 2001, Volume: 16, Issue:4

    Topics: Acarbose; Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic;

2001
Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    Diabetes research and clinical practice, 2001, Volume: 52, Issue:2

    Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; H

2001
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
    Diabetes care, 2001, Volume: 24, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic;

2001
24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Diabetes & metabolism, 2001, Volume: 27, Issue:2 Pt 1

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Circadian Rhythm; Delayed-Action Preparations; Diabetes

2001
Mechanisms of acute and chronic hypoglycemic action of gliclazide.
    Acta diabetologica, 2000, Volume: 37, Issue:4

    Topics: Acute Disease; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Gliclazide; Glu

2000
Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2001, Volume: 33, Issue:6

    Topics: Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method;

2001
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Diabetes, 2001, Volume: 50, Issue:8

    Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug A

2001
[Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Terapevticheskii arkhiv, 2001, Volume: 73, Issue:4

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Follow-Up Studies; Free Radical Scavengers; G

2001
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
    Diabetologia, 2001, Volume: 44, Issue:9

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Diabetes Mellitus, Type 2; Diabe

2001
Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    The Journal of the Association of Physicians of India, 2001, Volume: 49

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glyburide; Humans; Hypoglycemic

2001
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
    Diabetes care, 1992, Volume: 15, Issue:8

    Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glic

1992
Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment.
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1

    Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Diabetes Mellitus, Type 2; Free Radical Scavenge

1992
The physiological action of gliclazide: beta-cell function and insulin resistance.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Amino Acids; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 2; Gliclazide; Glucose Clam

1991
Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Diet, Diabetic; Gliclazide; Glipizide; Gly

1991
The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 1991, Volume: 8, Issue:3

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Gl

1991
Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans

1991
Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
    Diabete & metabolisme, 1991, Volume: 17, Issue:1 Pt 2

    Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazide; Hum

1991
Comparison of secondary failure rate between three second generation sulphonylureas.
    Diabetes research (Edinburgh, Scotland), 1990, Volume: 13, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Follow-Up Studies; Gliclazide; Glipizide;

1990
The action of gliclazide on insulin secretion and insulin sensitivity in non-obese non-insulin dependent diabetic patients.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1990, Volume: 46, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose Tolerance Test; Humans; I

1990
Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
    Diabetes research and clinical practice, 1988, Jan-07, Volume: 4, Issue:2

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie

1988
[Diamicron in the treatment of diabetes mellitus type 2].
    Sovetskaia meditsina, 1987, Issue:7

    Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic A

1987
Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
    Diabetes research and clinical practice, 1988, Jul-13, Volume: 5, Issue:2

    Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diet, Diabetic; Female; Gliclazide; Humans; Hypogly

1988
Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
    Diabete & metabolisme, 1986, Volume: 12, Issue:6

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-

1986
Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
    Current medical research and opinion, 1985, Volume: 9, Issue:10

    Topics: Aged; Chlorpropamide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Gl

1985

Other Studies

195 other studies available for gliclazide and Diabetes Mellitus, Adult-Onset

ArticleYear
Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents.
    Bioorganic & medicinal chemistry, 2009, Jul-15, Volume: 17, Issue:14

    Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dos

2009
Evaluation of the effectiveness and tolerability of gliclazide modified release 60 mg in patients with type 2 diabetes observing fasting during Ramadan in Pakistan: An analysis from the global DIA-RAMADAN study.
    Diabetes research and clinical practice, 2021, Volume: 181

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Humans; Hypoglycemic Agents; Islam; P

2021
Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting.
    Acta medica Indonesiana, 2022, Volume: 54, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glycated Hemoglobin; Humans; Hypoglyc

2022
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes.
    Journal of the American College of Cardiology, 2022, 09-20, Volume: 80, Issue:12

    Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Heart Disease Risk F

2022
Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography
    Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:5

    Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gliclazide;

2023
Optimal dosing of gliclazide-A model-based approach.
    Basic & clinical pharmacology & toxicology, 2023, Volume: 133, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose; Glycated Hemoglobin; Humans; Hypoglyc

2023
Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus.
    Journal of the ASEAN Federation of Endocrine Societies, 2023, Volume: 38, Issue:1

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2023
Real-world evidence on health-related quality of life in patients with type 2 diabetes mellitus using sulphonylureas: An analysis of the Joint Asia Diabetes Evaluation (JADE) Register.
    Diabetes research and clinical practice, 2023, Volume: 203

    Topics: Adult; Asia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Gliclazide; Glycated Hemoglobin; Hu

2023
ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes.
    The Journal of the Association of Physicians of India, 2023, Volume: 71, Issue:8

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Prospective Studies

2023
Preclinical and clinical results regarding the effects of a plant-based antidiabetic formulation versus well established antidiabetic molecules.
    Pharmacological research, 2019, Volume: 150

    Topics: Aged; Animals; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fem

2019
Observational analyses from ADVANCE and ADVANCE-ON.
    Diabetes, obesity & metabolism, 2020, Volume: 22 Suppl 2

    Topics: Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents

2020
Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
    Scientific reports, 2019, 11-22, Volume: 9, Issue:1

    Topics: Animals; Biological Availability; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diab

2019
A case of severe relapsing sulphonylurea-induced hypoglycaemia.
    BMJ case reports, 2019, Dec-02, Volume: 12, Issue:12

    Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemia; Middle Aged; Renal Insufficienc

2019
Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes.
    Therapeutic delivery, 2020, Volume: 11, Issue:3

    Topics: Animals; Bile Acids and Salts; Capsules; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glicl

2020
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
    Vascular health and risk management, 2020, Volume: 16

    Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie

2020
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
    Medicine, 2020, Jul-17, Volume: 99, Issue:29

    Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent

2020
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:12

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glycated Hemoglobin; Humans

2020
Visualized analysis and evaluation of simultaneous controlled release of metformin hydrochloride and gliclazide from sandwiched osmotic pump capsule.
    Drug development and industrial pharmacy, 2020, Volume: 46, Issue:11

    Topics: Animals; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dogs; Drug Delivery Systems; Glicla

2020
Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2020, Volume: 26, Issue:5

    Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Gliclazid

2020
Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.
    Journal of endocrinological investigation, 2021, Volume: 44, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Fatty Liver; Female; Follow-U

2021
The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function.
    The Journal of clinical endocrinology and metabolism, 2021, 06-16, Volume: 106, Issue:7

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female;

2021
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
    European journal of gastroenterology & hepatology, 2022, 01-01, Volume: 34, Issue:1

    Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformi

2022
Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients' response to gliclazide-modified-release-treated.
    Journal of biomedical informatics, 2021, Volume: 118

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Metabolic Networks and Pathways;

2021
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
    The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5

    Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combi

2017
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
    Cardiovascular diabetology, 2017, 07-27, Volume: 16, Issue:1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Fem

2017
Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.
    The Journal of the Association of Physicians of India, 2017, Volume: 65, Issue:6

    Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gl

2017
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Diabetes care, 2017, Volume: 40, Issue:11

    Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus

2017
Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method.
    Journal of proteome research, 2018, 04-06, Volume: 17, Issue:4

    Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Female; Gas Chro

2018
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:7

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; D

2018
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
    International journal of clinical practice, 2018, Volume: 72, Issue:4

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide

2018
Is gliclazide a new antidiabetic drug implicated in the pathogenesis of ocular mucous membrane pemphigoid?
    European journal of dermatology : EJD, 2018, Jun-01, Volume: 28, Issue:3

    Topics: Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Pemph

2018
Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report.
    BMC research notes, 2018, May-21, Volume: 11, Issue:1

    Topics: Antifungal Agents; Diabetes Mellitus, Type 2; Drug Interactions; Fluconazole; Gliclazide; Humans; Hy

2018
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Diabetes & metabolism, 2018, Volume: 44, Issue:4

    Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female;

2018
Reactive Oxygen Species-mediated Degradation of Antidiabetic Compounds: Cytotoxic Implications of Their Photodegradation Products.
    Photochemistry and photobiology, 2018, Volume: 94, Issue:6

    Topics: Animals; Biotransformation; Cell Survival; Chlorocebus aethiops; Diabetes Mellitus, Type 2; Gliclazi

2018
Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 106

    Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Dosage Calcul

2018
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Diabetes research and clinical practice, 2019, Volume: 152

    Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio

2019
Refraction paradox in diabetics: an extreme case of transient hyperopia.
    Journal of diabetes, 2013, Volume: 5, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans;

2013
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    European journal of endocrinology, 2013, Volume: 169, Issue:1

    Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol

2013
Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Alberta; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Typ

2014
Acute generalized exanthematous pustulosis induced by gliclazide: a case report.
    International journal of dermatology, 2013, Volume: 52, Issue:12

    Topics: Acute Generalized Exanthematous Pustulosis; Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Hum

2013
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:2

    Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Combinations; Female; Gl

2014
Parsimonious model for blood glucose level monitoring in type 2 diabetes patients.
    Biomedical and environmental sciences : BES, 2014, Volume: 27, Issue:7

    Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide;

2014
Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
    Current diabetes reviews, 2014, Volume: 10, Issue:5

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Metform

2014
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Diabetes research and clinical practice, 2015, Volume: 107, Issue:1

    Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina

2015
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Journal of diabetes and its complications, 2015, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular

2015
Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Diabetes & metabolism, 2015, Volume: 41, Issue:3

    Topics: Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agen

2015
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
    Canadian journal of diabetes, 2015, Volume: 39, Issue:4

    Topics: Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fem

2015
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
    Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:9

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2;

2016
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat

2016
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2016, Volume: 63, Issue:5

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gl

2016
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Re

2016
CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.
    Journal of diabetes investigation, 2016, Volume: 7, Issue:5

    Topics: Blood Glucose; China; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Female; Genotype; Gliclazi

2016
When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2016, Volume: 66, Issue:647

    Topics: Adult; Age of Onset; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; General Practice; G

2016
A case of bullous pemphigoid ınduced by vildagliptin.
    Cutaneous and ocular toxicology, 2017, Volume: 36, Issue:2

    Topics: Adamantane; Administration, Cutaneous; Clobetasol; Complement C3; Diabetes Mellitus, Type 2; Dipepti

2017
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    Diabetologia, 2016, Volume: 59, Issue:12

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations

2016
Treatment of Type 2 Diabetes with a Breakable Extended Release Gliclazide Formulation in Primary Care: The Xrise Study.
    The Journal of the Association of Physicians of India, 2015, Volume: 63, Issue:12

    Topics: Adult; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combinat

2015
Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
    Diabetes care, 2008, Volume: 31, Issue:10

    Topics: Amino Acid Substitution; ATP-Binding Cassette Transporters; Blood Glucose; China; Cohort Studies; Di

2008
Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2008, Volume: 30, Issue:5

    Topics: Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes M

2008
Sulphonylureas and cancer: a case-control study.
    Acta diabetologica, 2009, Volume: 46, Issue:4

    Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glybur

2009
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:1

    Topics: Adult; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypertension; Infant, Newborn; Live Bi

2009
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:3

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Pepti

2009
Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge.
    British journal of clinical pharmacology, 2009, Volume: 67, Issue:2

    Topics: Aged; Cholecystectomy; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypertension; Hypoglycemia; Ma

2009
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
    Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:2

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gl

2009
Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:1

    Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Melli

2009
Pioglitazone-induced acute rhabdomyolysis.
    Diabetes care, 2009, Volume: 32, Issue:7

    Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Male; Muscl

2009
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
    International journal of clinical practice, 2009, Volume: 63, Issue:10

    Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fastin

2009
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    Diabetologia, 2009, Volume: 52, Issue:11

    Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A

2009
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Diabetes research and clinical practice, 2009, Volume: 86, Issue:3

    Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti

2009
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Metabolism: clinical and experimental, 2010, Volume: 59, Issue:9

    Topics: Aged; alpha-2-Antiplasmin; Antithrombin III; Azides; Blood Glucose; Body Mass Index; Deoxyuracil Nuc

2010
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
    Endocrine journal, 2010, Volume: 57, Issue:6

    Topics: Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Family Practice; Gliclazide

2010
Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
    International journal of clinical practice, 2010, Volume: 64, Issue:8

    Topics: Adult; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Sc

2010
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
    Arquivos brasileiros de endocrinologia e metabologia, 2010, Volume: 54, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gli

2010
[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
    Kardiologiia, 2010, Volume: 50, Issue:5

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Data Interpretation, Statis

2010
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
    Diabetes research and clinical practice, 2010, Volume: 90, Issue:3

    Topics: Aged; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glipizide; Glybur

2010
Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.
    Diabetologia, 2011, Volume: 54, Issue:2

    Topics: Animals; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Glycogen; Lactic Acid; Male; Myocardial I

2011
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
    European journal of pharmacology, 2011, Feb-25, Volume: 653, Issue:1-3

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia

2011
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Current medical research and opinion, 2011, Volume: 27, Issue:7

    Topics: Adamantane; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting;

2011
Diagnosis in diabetes: does it matter?
    The journal of the Royal College of Physicians of Edinburgh, 2011, Volume: 41, Issue:2

    Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Glucokinase; Hepatocyte Nuclear Factor 1-alpha; Human

2011
High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin.
    Analytical and bioanalytical chemistry, 2011, Volume: 401, Issue:9

    Topics: Binding Sites; Binding, Competitive; Calibration; Carrier Proteins; Chromatography, Affinity; Diabet

2011
Dissolution rate enhancement of gliclazide by ordered mixing.
    Acta pharmaceutica (Zagreb, Croatia), 2011, Sep-01, Volume: 61, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Carriers; Drug Compounding; Drug Delivery Systems; Excipients; Glicl

2011
Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
    Endocrine research, 2012, Volume: 37, Issue:1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide

2012
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:3

    Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Exp

2012
Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus.
    The Medical journal of Malaysia, 2012, Volume: 67, Issue:1

    Topics: Blood Glucose; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female

2012
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Diabetes research and clinical practice, 2012, Volume: 98, Issue:1

    Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Typ

2012
Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
    Basic & clinical pharmacology & toxicology, 2012, Volume: 111, Issue:4

    Topics: Animals; Cell Death; Cell Line; Cluster Analysis; Diabetes Mellitus, Type 2; Gene Regulatory Network

2012
Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathi

2012
Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.
    Endocrine journal, 2002, Volume: 49, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazi

2002
Diabetes mellitus and weight control: differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls.
    Nutrition (Burbank, Los Angeles County, Calif.), 2003, Volume: 19, Issue:2

    Topics: Calorimetry, Indirect; Carbon Dioxide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclaz

2003
Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
    Annals of clinical biochemistry, 2003, Volume: 40, Issue:Pt 3

    Topics: Acetylglucosaminidase; Administration, Oral; Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Fem

2003
[Compliance and optimisation of oral antidiabetic therapy. A longitudinal study].
    Presse medicale (Paris, France : 1983), 2004, Feb-14, Volume: 33, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Chi-Square Distribution; Cohort

2004
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2004, Volume: 64, Issue:3

    Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ

2004
Octreotide treatment for sulfonylurea-induced hypoglycaemia.
    The Medical journal of Australia, 2004, May-17, Volume: 180, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypogly

2004
[Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].
    MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Gliclazide; Glycated Hemogl

2004
[Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?].
    Praxis, 2004, Sep-29, Volume: 93, Issue:40

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dru

2004
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
    MMW Fortschritte der Medizin, 2004, Jul-22, Volume: 146, Issue:29-30

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug

2004
The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2005, Volume: 113, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Homeostasis; Humans; Hypoglycemic Age

2005
[54-year-old patient with type 2 diabetes mellitus and increased blood pressure values].
    Praxis, 2005, Mar-16, Volume: 94, Issue:11

    Topics: Antihypertensive Agents; Blood Pressure Determination; Combined Modality Therapy; Coronary Disease;

2005
Gliclazide modified release.
    Drugs, 2005, Volume: 65, Issue:10

    Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Gliclazide; Hu

2005
Management of diabetes during Ramadan.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22 Suppl 4

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Gliclazide; Humans;

2005
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
    Journal of pharmacokinetics and pharmacodynamics, 2006, Volume: 33, Issue:3

    Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type

2006
Effects of gliclazide beyond metabolic control.
    Metabolism: clinical and experimental, 2006, Volume: 55, Issue:5 Suppl 1

    Topics: Antioxidants; Diabetes Complications; Diabetes Mellitus, Type 2; DNA Damage; Gliclazide; Humans; Hyp

2006
Lymphocyte ecto-5'-nucleotidase in obese type 2 diabetic patients treated with gliclazide.
    Diabetes & metabolism, 2006, Volume: 32, Issue:2

    Topics: 5'-Nucleotidase; Adenosine; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabet

2006
Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin.
    Postgraduate medical journal, 2006, Volume: 82, Issue:969

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Insulin R

2006
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Diabetes/metabolism research and reviews, 2007, Volume: 23, Issue:6

    Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies;

2007
Insulinoma causing hypoglycemia in a patient with type 2 diabetes.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2007, Volume: 106, Issue:5

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglyc

2007
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
    Physiological research, 2009, Volume: 58, Issue:2

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab

2009
In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM).
    Chemico-biological interactions, 2008, Jun-17, Volume: 173, Issue:3

    Topics: Aged; Cell Separation; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; DNA Repair; Female; Glicl

2008
[Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Schweizerische medizinische Wochenschrift, 1984, Feb-25, Volume: 114, Issue:8

    Topics: Blood Glucose; Calorimetry, Indirect; Cholesterol; Diabetes Mellitus, Type 2; Energy Metabolism; Fem

1984
Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
    Current medical research and opinion, 1984, Volume: 9, Issue:1

    Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucagon;

1984
Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes.
    Thrombosis research, 1984, Jul-01, Volume: 35, Issue:1

    Topics: Aged; Chlorpropamide; Diabetes Mellitus, Type 2; Endothelium; Female; Fibrinogen; Fibrinolysis; Glic

1984
Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
    The Tohoku journal of experimental medicine, 1983, Volume: 141 Suppl

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Gliclazide; Glyburide; Humans;

1983
[Experience with diamicron treatment of diabetics].
    Klinicheskaia meditsina, 1984, Volume: 62, Issue:11

    Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Evaluation; Dru

1984
[Preliminary report on 30 cases of non-insulin-dependent diabetes (NIDD) treated with gliclazide].
    Zhonghua nei ke za zhi, 1983, Volume: 22, Issue:7

    Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male; Middle Aged; Sulfonylurea Compounds

1983
Lack of weight gain with gliclazide treatment for 30 months in type II diabetes.
    Current medical research and opinion, 1984, Volume: 9, Issue:1

    Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male

1984
Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.
    Acta diabetologica, 1995, Volume: 32, Issue:1

    Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Forensic Medicine;

1995
Gliclazide in the treatment of obese NIDDM patients.
    The Journal of the Association of Physicians of India, 1994, Volume: 42, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Human

1994
Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:1

    Topics: Adult; Aged; Base Sequence; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucose; Glucose Clamp Te

1995
Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages.
    Atherosclerosis, 1994, Volume: 105, Issue:2

    Topics: Adult; Animals; Cells, Cultured; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship,

1994
Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
    The Journal of the Association of Physicians of India, 1993, Volume: 41, Issue:6

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans

1993
Possible gliclazide-induced water retention with azotemia.
    Internal medicine (Tokyo, Japan), 1994, Volume: 33, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Edema; Female;

1994
Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus.
    Changgeng yi xue za zhi, 1993, Volume: 16, Issue:4

    Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Islets of Langerhans;

1993
[Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?].
    Polskie Archiwum Medycyny Wewnetrznej, 1993, Volume: 89, Issue:4

    Topics: Adult; Aged; Blood Platelets; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Mi

1993
Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM).
    Diabetes research and clinical practice, 1993, Volume: 20, Issue:2

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Tolerance Test; Humans

1993
[Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
    Polskie Archiwum Medycyny Wewnetrznej, 1993, Volume: 89, Issue:6

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Insul

1993
[Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1993, Volume: 48 Suppl 1

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Sulfonylurea Compound

1993
[Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1993, Volume: 48 Suppl 1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Middle Aged; Platel

1993
Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
    Diabetologia, 1995, Volume: 38, Issue:10

    Topics: Adult; Aged; Animals; Base Sequence; Biopsy; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; DN

1995
Elevation and fluctuation of serum CA 19-9 and SPAN-1 levels after administration of sulfonylurea in a diabetic patient with Lewis(a-,b-) blood phenotype.
    Diabetes care, 1995, Volume: 18, Issue:10

    Topics: Antigens, Neoplasm; Blood Glucose; CA-19-9 Antigen; Carcinoembryonic Antigen; Diabetes Mellitus, Typ

1995
Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
    The New Zealand medical journal, 1997, May-23, Volume: 110, Issue:1044

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Hormones; Humans; Hypoglycemia; Hypogl

1997
Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
    Diabetic medicine : a journal of the British Diabetic Association, 1997, Volume: 14, Issue:9

    Topics: Administration, Oral; Aged; Blood Glucose; Circadian Rhythm; Cohort Studies; Diabetes Mellitus, Type

1997
The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1

    Topics: Administration, Oral; Adult; Antioxidants; Ascorbic Acid; Coronary Artery Disease; Diabetes Mellitus

1997
Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus.
    British journal of clinical pharmacology, 1998, Volume: 45, Issue:3

    Topics: Adult; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Lymphocy

1998
Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
    Diabetes care, 1998, Volume: 21, Issue:4

    Topics: Animals; Aorta; Arteriosclerosis; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; C

1998
Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats.
    European journal of pharmacology, 1998, Nov-20, Volume: 361, Issue:2-3

    Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose Toleran

1998
Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection.
    Diabetic medicine : a journal of the British Diabetic Association, 1998, Volume: 15 Suppl 4

    Topics: Amputation, Surgical; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic

1998
Antioxidant effects of gliclazide and soluble adhesion molecules in type 2 diabetes.
    Diabetes care, 1999, Volume: 22, Issue:3

    Topics: Antioxidants; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Gliclazide; Humans; Solubility

1999
Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent.
    Prescrire international, 1998, Volume: 7, Issue:36

    Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evalua

1998
Gliclazide-induced acute hepatitis.
    European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:1

    Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female;

2000
Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:2 Suppl 1

    Topics: Adult; Cell Adhesion; Cells, Cultured; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Gli

2000
Eosinophilic pleural effusion due to gliclazide.
    Respiratory medicine, 2000, Volume: 94, Issue:1

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Pleural Effus

2000
Gliclazide, a better choice for type 2 diabetes.
    The Journal of the Association of Physicians of India, 1999, Volume: 47, Issue:10

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Treatment Outcome

1999
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
    Diabetes care, 2000, Volume: 23, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati

2000
Interaction of gliclazide and rifampicin.
    Diabetes care, 2000, Volume: 23, Issue:8

    Topics: Aged; Antibiotics, Antitubercular; Clarithromycin; Diabetes Mellitus, Type 2; Drug Interactions; Dru

2000
Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
    Clinical chemistry, 2000, Volume: 46, Issue:11

    Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdose; Electrophores

2000
Type 2 diabetes: to stimulate or not to stimulate the beta cell.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Suppl 2

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Isle

2000
Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2000, Volume: 10, Issue:4

    Topics: Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LD

2000
[Reclid effects on carbohydrate, lipid metabolism, lipid peroxidation and hemodynamics in patients with diabetes mellitus type 2].
    Klinicheskaia meditsina, 2000, Volume: 78, Issue:11

    Topics: Carbohydrates; Diabetes Mellitus, Type 2; Female; Gliclazide; Hemodynamics; Humans; Hypoglycemic Age

2000
Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.
    Clinical science (London, England : 1979), 2001, Volume: 101, Issue:5

    Topics: Adult; Aged; Case-Control Studies; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2;

2001
Does gliclazide stimulate first-phase, second-phase, or both phases of insulin release?
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2002, Volume: 34, Issue:2

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin

2002
Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
    The Korean journal of internal medicine, 1992, Volume: 7, Issue:2

    Topics: Antigens; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fibrinolys

1992
Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
    Diabetes research and clinical practice, 1992, Volume: 17, Issue:2

    Topics: Administration, Oral; Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gliclazi

1992
Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Diabetes research and clinical practice, 1992, Volume: 18, Issue:1

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com

1992
[Acute pancreatitis induced by gliclazide].
    Gastroenterologie clinique et biologique, 1992, Volume: 16, Issue:1

    Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Male; Pancreatitis

1992
Effect of gliclazide on platelet-activating factor-induced platelet aggregation in patients with non-insulin-dependent diabetes mellitus.
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1

    Topics: Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Gliclazide; Humans; In Vitro Techniques; Male

1992
Thromboxane/prostacyclin balance in type II diabetes: gliclazide effects.
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1

    Topics: Diabetes Mellitus, Type 2; Epoprostenol; Gliclazide; Humans; Lipids; Thromboxane A2

1992
Gliclazide therapy of NIDDM in the 90s. Proceedings of 1st International Diamicron Symposium, September 24, 1990, Montreal, Canada.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans

1991
The effect of Diamicron on the secretion and action of insulin.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Secretion; Kinetics;

1991
Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazid

1991
Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients.
    Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Follow-Up Studies; G

1991
Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gliclazide; Insu

1991
Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
    Diabetes research and clinical practice, 1991, Volume: 12, Issue:3

    Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mel

1991
Oral treatment of diabetes mellitus: the contribution of gliclazide.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans

1991
Oral treatment of diabetes mellitus: the contribution of gliclazide. Proceedings of a symposium, September 23, 1989, Lisbon, Portugal.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Gliclazide; Humans

1991
Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Insulin; Insulin In

1991
An evaluation of long-term glycemic control in non-insulin-dependent diabetes mellitus: the relevance of glycated hemoglobin.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Huma

1991
Development of macroangiopathy in sand rats (Psammomys obesus), an animal model of non-insulin-dependent diabetes mellitus: effect of gliclazide.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Animals; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Ani

1991
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.
    The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A

    Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fibrinolysis; Gliclazide; Humans; Male;

1991
1H nuclear magnetic resonance and clinical studies of interaction of calcium antagonists and hypoglycemic sulfonylureas.
    Fundamental & clinical pharmacology, 1991, Volume: 5, Issue:6

    Topics: Adenosine Triphosphate; Aged; Binding Sites; Blood Glucose; Calcimycin; Calcium; Chromatography, Gas

1991
The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.
    European journal of clinical pharmacology, 1990, Volume: 38, Issue:5

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Gliclazide; Humans; Insulin

1990
The effect of timing on gliclazide absorption and action.
    Hiroshima journal of medical sciences, 1990, Volume: 39, Issue:1

    Topics: Absorption; Adult; Aged; Diabetes Mellitus, Type 2; Female; Food; Gliclazide; Humans; Male; Middle A

1990
[Spectrum of erythrocyte membrane lipids in various types of hypoglycemic therapy].
    Sovetskaia meditsina, 1990, Issue:6

    Topics: Biguanides; Cholesterol; Chromatography; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Female; Gl

1990
Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide).
    Journal of internal medicine, 1989, Volume: 225, Issue:4

    Topics: Aged; Diabetes Mellitus, Type 2; Fibrinolysis; Gliclazide; Humans; Middle Aged; Sulfonylurea Compoun

1989
Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
    Diabetologia, 1989, Volume: 32, Issue:8

    Topics: Animals; Animals, Newborn; Arginine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellit

1989
Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients.
    Diabetes, 1989, Volume: 38, Issue:11

    Topics: ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Gliclazide; Glucose; Glycogen Synthase

1989
Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Metabolism: clinical and experimental, 1989, Volume: 38, Issue:8

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gliclazide; Glucose Clamp Techniqu

1989
The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.
    Australian and New Zealand journal of medicine, 1989, Volume: 19, Issue:1

    Topics: Adult; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Insulin; Insulin Sec

1989
Gliclazide alcohol flush.
    Diabetes care, 1989, Volume: 12, Issue:1

    Topics: Chlorpropamide; Diabetes Mellitus, Type 2; Ethanol; Flushing; Gliclazide; Humans; Male; Middle Aged;

1989
Effect of sulphonylurea administration on insulin secretion and amino acid metabolism in non-insulin-dependent diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 1985, Volume: 2, Issue:1

    Topics: Adult; Aged; Amino Acids; Amino Acids, Branched-Chain; Blood Glucose; Diabetes Mellitus, Type 2; Fem

1985
Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial.
    Diabetic medicine : a journal of the British Diabetic Association, 1985, Volume: 2, Issue:6

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Moni

1985
[Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
    Bollettino della Societa italiana di biologia sperimentale, 1988, Volume: 64, Issue:9

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female;

1988
Effect of gliclazide on non-insulin dependent diabetes mellitus.
    Advances in experimental medicine and biology, 1988, Volume: 246

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Tolerance Test; Humans; Insul

1988
[Hemorheologic, metabolic and blood coagulation changes in diabetics in treatment with sulfanyl ureas].
    Minerva medica, 1988, Volume: 79, Issue:5

    Topics: Blood Coagulation; Blood Viscosity; Diabetes Mellitus, Type 2; Erythrocyte Deformability; Gliclazide

1988
Effect of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG and lipid peroxides in non-insulin dependent diabetes mellitus.
    Diabetes research (Edinburgh, Scotland), 1988, Volume: 9, Issue:2

    Topics: Aged; Blood Proteins; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glyburide; Glycat

1988
[Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors].
    Terapevticheskii arkhiv, 1988, Volume: 60, Issue:12

    Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Gliclazide; Gluco

1988
Plasma activity of the enzyme N-acetil-beta-glucosaminidase in healthy and diabetic subjects: effects of treatment with a sulfonylurea drug.
    Advances in experimental medicine and biology, 1988, Volume: 246

    Topics: Acetylglucosaminidase; Adult; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus,

1988
A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:2

    Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Insu

1988
[Non-insulin-dependent diabetes and gliclazide].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1986

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Resistance; Insulin Secretion; Sulfo

1986
[Gliclazide in the non-insulin-dependent diabetic patient in geriatrics].
    Wiener medizinische Wochenschrift (1946), 1988, Mar-15, Volume: 138, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gli

1988
New oral hypoglycemic drug--gliclazide--in the treatment of maturity onset diabetes mellitus.
    Indian journal of medical sciences, 1988, Volume: 42, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male; Middle

1988
[The importance of gliclazide in clinical practice].
    Vnitrni lekarstvi, 1988, Volume: 34, Issue:6

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Sulfonylurea Compounds

1988
Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.
    Current medical research and opinion, 1986, Volume: 10, Issue:5

    Topics: Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Carbohydrates;

1986
Gliclazide--oral hypoglycaemic agent.
    The Australian nurses' journal. Royal Australian Nursing Federation, 1985, Volume: 15, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Interactions; Gliclazide; Humans; Sulfonylurea Compounds

1985
Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
    Diabetes, 1985, Volume: 34, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Erythrocytes; Female; Gliclazide;

1985
Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
    Pharmatherapeutica, 1985, Volume: 4, Issue:2

    Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin;

1985
Gliclazide: the effects on lipids in type II diabetes.
    Irish journal of medical science, 1985, Volume: 154, Issue:3

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Lipids; Mal

1985